<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0905233607
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TULIP 40 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ATORVASTATIN CALCIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        31.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LEK S.A" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LEK S.A
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AA05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tulip belongs to a group of medicines known as statins, which are lipid (fat) regulating medicines.</p><p>Tulip is used to lower lipids known as cholesterol and triglycerides in the blood when a low fat diet and life style changes on their own have failed. If you are at an increased risk of heart disease, Tulip can also be used to reduce such risk even if your cholesterol levels are normal. You should maintain a standard cholesterol lowering diet during</p><p>treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>DO NOT take Tulip:</strong></p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to atorvastatin or any of the other ingredients of this medicine (listed in section 6).</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have or have ever had a disease which affects the liver</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had any unexplained abnormal blood tests for liver function</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are a woman able to have children and not using reliable contraception</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant or trying to become pregnant</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are breast-feeding</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you use the combination of glecaprevir/pibrentasvir in the treatment of hepatitis C.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before taking Tulip:</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe respiratory failure</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking or have taken in the last 7 days a medicine called fusidic acid, (a medicine for bacterial infection) orally or by injection. The combination of fusidic acid and Tulip can lead to serious muscle problems (rhabdomyolysis)</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had a previous stroke with bleeding into the brain, or have small pockets of fluid in the brain from previous strokes</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have kidney problems</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an under-active thyroid gland (hypothyroidism)</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had repeated or unexplained muscle aches or pains, a personal history or family history of muscle problems</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had previous muscular problems during treatment with other lipid-lowering medicines (e.g. other &lsquo;-statin&rsquo; or &lsquo;-fibrate&rsquo; medicines)</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you regularly drink a large amount of alcohol</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a history of liver disease</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are older than 70 years.</p><p>&nbsp;</p><p>If any of these apply to you, your doctor will need to carry out a blood test before and possibly during your Tulip treatment to predict your risk of muscle related side effects. The risk of muscle related side effects e.g. rhabdomyolysis is known to increase when certain medicines are taken at the same time (see section 2 &ldquo;Other medicines and Tulip&rdquo;).</p><p>&nbsp;</p><p>Also tell your doctor or pharmacist if you have a muscle weakness that is constant. Additional tests and medicines may be needed to diagnose and treat this.</p><p>&nbsp;</p><p>While you are on this medicine your doctor will monitor you closely if you have diabetes or are at risk of developing diabetes. You are likely to be at risk of developing diabetes if you have high levels</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; of sugars and fats in your blood, are overweight and have high blood pressure.</p><p>&nbsp;</p><p><strong>Other medicines and Tulip</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. There are some medicines that may change the effect of Tulip or their effect may be changed by Tulip. This type of interaction could make one or both of the medicines less effective. Alternatively it could increase the risk or severity of side- effects, including the important muscle wasting condition known as rhabdomyolysis described in section 4:</p><p>&nbsp;</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used to alter the way your immune system works, e.g. ciclosporin</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain antibiotics or antifungal medicines, e.g. erythromycin, clarithromycin, telithromycin, ketoconazole, itraconazole, voriconazole, fluconazole, posaconazole, rifampin</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines to regulate lipid levels, e.g. gemfibrozil, other fibrates, colestipol</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some calcium channel blockers used for angina or high blood pressure, e.g. amlodipine, diltiazem,; medicines to regulate your heart rhythm e.g. digoxin, verapamil, amiodarone</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used in the treatment of HIV e.g. ritonavir, lopinavir, atazanavir, indinavir, darunavir, the combination of tipranavir/ritonavir etc.</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some medicines used in the treatment of hepatitis C e.g. telaprevir, boceprevir and the combination of elbasvir/grazoprevir</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines known to interact with Tulip include ezetimibe (which lowers cholesterol), warfarin (which reduces blood clotting), oral contraceptives, stiripentol (an anti-convulsant for epilepsy), cimetidine (used for heartburn and peptic ulcers), phenazone (a painkiller), colchicine (used to treat gout), and antacids (indigestion products containing aluminium or magnesium)</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines obtained without a prescription: St John&rsquo;s Wort</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you need to take oral fusidic acid to treat a bacterial infection you will need to temporarily stop using this medicine. Your doctor will tell you when it is safe to restart Tulip. Taking Tulip]with fusidic acid may rarely lead to muscle weakness, tenderness or pain (rhabdomyolysis). See more information regarding rhabdomyolysis in section 4.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Tulip </strong><strong>with food, drink and alcohol</strong></p><p>See section 3 for instructions on how to take Tulip. Please note the following:</p><p>&nbsp;</p><p><em>Grapefruit juice</em></p><p>Do not take more than one or two small glasses of grapefruit juice per day because large quantities of grapefruit juice can change the effects of Tulip.</p><p>&nbsp;</p><p><em>Alcohol</em></p><p>Avoid drinking too much alcohol while taking this medicine. See section 2 &ldquo;Warnings and</p><p>&nbsp;</p><p>&nbsp;</p><p>precautions&rdquo; for details.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Do not take Tulip if you are pregnant, or if you are trying to become pregnant. Do not take Tulip if you are able to become pregnant unless you use reliable contraceptive measures.</p><p>Do not take Tulip if you are breast-feeding.</p><p>The safety of Tulip during pregnancy and breast-feeding has not yet been proven. Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Normally this medicine does not affect your ability to drive or operate machines. However, do not drive if this medicine affects your ability to drive. Do not use any tools or machines if your ability to use them is affected by this medicine.</p><p>&nbsp;</p><p>Tulip contains sodium. It contains less than 1 mmol sodium (23 mg) per film- coated tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Before starting treatment, your doctor will place you on a low-cholesterol diet, which you should maintain also during therapy with Tulip.</p><p>&nbsp;</p><p>The usual starting dose of Tulip is 10 mg once a day in adults and children aged 10 years or older. This may be increased if necessary by your doctor until you are taking the amount you need. Your doctor will adapt the dose at intervals of 4 weeks or more. The maximum dose of Tulip is 80 mg once a day.</p><p>&nbsp;</p><p>Tulip tablets should be swallowed whole with a drink of water, and can be taken at any time of day, with or without food. However, try to take your tablet at the same time every day.</p><p>&nbsp;</p><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>The duration of treatment with Tulip is determined by your doctor.</strong></p><p><strong>&nbsp;</strong></p><p>Please ask your doctor if you think that the effect of Tulip is too strong or too weak.</p><p>&nbsp;</p><p><strong>If you take more Tulip than you should</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>If you accidently take too many Tulip tablets (more than your usual daily dose), contact your doctor or nearest hospital for advice.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>If you forget to take Tulip</strong></p><p>If you forget to take a dose, just take your next scheduled dose at the correct time. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking Tulip</strong></p><p>If you have any further questions on the use of this medicine or wish to stop your treatment, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>If you experience any of the following serious side effects or symptoms, stop taking your tablets and tell your doctor immediately or go to the nearest hospital accident and emergency department.</strong></p><p><strong>&nbsp;</strong></p><p>Rare: may affect up to 1 in 1,000 people:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious allergic reaction which causes swelling of the face, tongue and throat that can cause great difficulty in breathing.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious illness with severe peeling and swelling of the skin, blistering of the skin, mouth, eyes genitals and fever. Skin rash with pink-red blotches especially on palms of hands or soles of feet which may blister.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle weakness, tenderness, pain, rupture or red-brown discolouration of urine and particularly, if at the same time, you feel unwell or have a high temperature it may be caused by an abnormal muscle breakdown (rhabdomyolysis). The abnormal muscle breakdown does not always go away, even after you have stopped taking atorvastatin, and it can be life-threatening and lead to kidney problems.</p><p>&nbsp;</p><p>Very rare: may affect up to 1 in 10,000 people:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience problems with unexpected or unusual bleeding or bruising, tiredness, loss of appetite, stomach pain, feeling sick, yellowing of your skin or eyes (jaundice), this may be suggestive of a liver complaint. You should consult your doctor as soon as possible.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lupus-like disease syndrome (including rash, joint disorders and effects on blood cells)</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Other possible side effects with Tulip:</strong></p><p><strong>&nbsp;</strong></p><p>Common (may affect up to 1 in 10 people):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the nasal passages, pain in the throat, nose bleed</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increases in blood sugar levels (if you have diabetes continue careful monitoring of your blood sugar levels), increase in blood creatine kinase</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea, constipation, wind, indigestion, diarrhoea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain, joint swelling, muscle pain, muscle spasms and back pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood test results that show your liver function can become abnormal</p><p>&nbsp;</p><p>Uncommon (may affect up to 1 in 100 people):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anorexia (loss of appetite), weight gain, decreases in blood sugar levels (if you have diabetes you should continue careful monitoring of your blood sugar levels)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Having nightmares, insomnia</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, numbness or tingling in the fingers and toes, reductions of sensation to pain or touch, change in sense of taste, loss of memory</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ringing in the ears and/or head</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting, belching, abdominal pain upper and lower, pancreatitis (inflammation of the pancreas leading to stomach pain)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatitis (liver inflammation)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, skin rash and itching, hives, hair loss</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neck pain, muscle fatigue</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue, feeling unwell, weakness, chest pain, swelling especially in the ankles (oedema), raised temperature</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urine tests that are positive for white blood cells</p><p>&nbsp;</p><p>Rare (may affect up to 1 in 1,000 people):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visual disturbance</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unexpected bleeding or bruising</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cholestasis (yellowing of the skin and whites of the eyes)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tendon injury</p><p>&nbsp;</p><p>Very rare (may affect up to 1 in 10,000 people):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An allergic reaction - symptoms may include sudden wheezing and chest pain or tightness, swelling of the eyelids, face, lips, mouth, tongue or throat, difficulty breathing, collapse</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hearing loss</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gynaecomastia (breast enlargement in men).</p><p>&nbsp;</p><p>Not known (frequency cannot be estimated from the available data):</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle weakness that is constant</p><p>&nbsp;</p><p>Possible side effects reported with some statins (medicines of the same type):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sexual difficulties</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breathing problems including persistent cough and/or shortness of breath or fever</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes. This is more likely if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure. Your doctor will monitor you while you are taking this medicine.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and the blister after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&ordm;C.</p><p>&nbsp;&nbsp;&nbsp; Store in the original package, in order to protect from moisture.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is atorvastatin (as calcium salt).</p><p>Each film-coated tablet contains 10 mg of atorvastatin (as calcium salt). Each film-coated tablet contains 20 mg of atorvastatin (as calcium salt). Each film-coated tablet contains 40 mg of atorvastatin (as calcium salt). Each film-coated tablet contains 80 mg of atorvastatin (as calcium salt).</p><p>&nbsp;</p><p>&nbsp;</p><p>The other ingredients are sodium lauryl sulfate, microcrystalline cellulose, colloidal anhydrous silica, maize starch pregelatinised, trometamol, iron oxide yellow (E 172), magnesium stearate, talc, sodium starch glycolate (type A), carmellose sodium, glycerol and hydroxyethylcellulose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10 mg film-coated tablets:
Light yellow, dappled, glossy, round biconvex film-coated tablets, debossed with “HLA 10” on one side measuring 7.2 mm in diameter.

20 mg film-coated tablets:
Light yellow, dappled, glossy, round biconvex film-coated tablets, debossed with “HLA 20” on one side measuring 9.2 mm in diameter.



40 mg film-coated tablets:
Light yellow, dappled, glossy, round biconvex film-coated tablets, debossed with “HLA 40” on one side measuring 11.2 mm in diameter.

80 mg film-coated tablets:
Light yellow, dappled, glossy, oval biconvex film-coated tablets, debossed with “HLA 80” on one side measuring 19.3 mm in length.

The film-coated tablets are packed in aluminium/aluminium blisters which are inserted in a carton folder.
[AT/H/0305 10 mg]
Pack sizes: 7, 14, 28, 30, 56, 60, 63, 90, 91, 100 film-coated tablets

[AT/H/0305 20 mg]
Pack sizes: 7, 14, 28, 30, 56, 60, 63, 90, 91, 100 film-coated tablets

 

[AT/H/0305 40 mg]
Pack sizes: 7, 14, 28, 30, 56, 60, 63, 90, 91, 100 film-coated tablets

[AT/H/0305 80 mg]
Pack sizes: 7, 28, 30, 50, 60, 90, 98, 100 film-coated tablets
[AT/H/0308 10 mg, 20 mg, 40 mg, 80 mg]
Pack sizes: 7, 10, 14, 20, 21, 28, 30, 35, 42, 49, 50, 56, 60, 63, 70, 77, 84, 90, 91, 98, 100 film-coated
tablets

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;Lek Pharmaceuticals d.d.</p><p>&nbsp;Ljubljana</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                09/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي عقار توليب إلى مجموعة من الأدوية تُعرَف باسم الستاتينات، وهي أدوية تعمل على تنظيم الدهون.</p><p dir="RTL">يُستَخدَم عقار توليب لخفض الدهون التي تُعرَف باسم الكوليسترول والدهون الثلاثية في الدَّم عند فشل النظام الغذائي منخفض الدهون وإجراء تغييرات على نمط الحياة في تحقيق ذلك من تلقاء نفسه. إذا كنت مُعَرَّضًا لخطورة مرتفعة للإصابة بمرض قلبي، فيُمكِن أيضًا استخدام عقار توليب لخفض هذه الخطورة حتى إذا كانت مستويات الكوليسترول لديك طبيعية. يجب عليك مواصلة اتباع نظام غذائي قياسي خافض للكوليسترول أثناء</p><p dir="RTL">العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول عقار توليب في الحالات التَّالية</strong><strong>:</strong></p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه أتورفاستاتين أو تجاه أيٍّ من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: 6)</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني أو قد عانيت من قبل من مرض يُؤثر على الكبد.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت أيٌّ من نتائج اختبارات وظائف الكبد لديك غير طبيعية وغير مبررة.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ سيدة لديكِ القدرة على الإنجاب ولا تستخدمين وسيلة موثوقة لمنع الحَمْل.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا أو تحاولين الإنجاب.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مرضعًا.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم تركيبة من جليكابريفير/بيبرنتاسفير في علاج التهاب الكبد من النوع &quot;سي&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي أو الممرض(ة) الخاص(ة) بك قبل تناوُل عقار توليب:</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من فشلٍ تنفسي شديد.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى أو قد تلقيت في الأيام السبعة الأخيرة دواءً يُسمى حمض الفوسيديك (دواء يُستَخدَم لعلاج العدوى البكتيرية) عن طريق الفم أو الحَقْن. يُمكِن أن يؤدي تناوُل حمض الفوسيديك بمصاحبة عقار توليب إلى مشاكل عضلية خطيرة (انحلال الربيدات).</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصِبت من قبل بسكتة دماغية مصحوبة بنزيف داخل المخ، أو لديك جيوب صغيرة بالمخ تحتوي على سائل جرَّاء سكتات دماغية سابقة.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالكلى.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُصابًا بقصور في نشاط الغدة الدرقية.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تعرَّضت لأوجاع أو آلام عضلية مُتكَررة وغير مُبَررة، أو لديك تاريخ مَرَضي شخصي أو عائلي من مشاكل العضلات.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من مشاكل عضلية سابقة أثناء العلاج بأدوية أخرى خافضة للدهون (على سبيل المثال: غيرها من أدوية &quot;الستاتين&quot; أو &quot;الفيبرات&quot;).</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تشرب كمية كبيرة من الكحوليات بصفة منتظمة.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ مرضي من الإصابة بأمراض الكبد.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان عمرك يتجاوز 70 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا انطبق عليك أيٌّ من هذه الأمور، فسيحتاج طبيبك إلى إجراء اختبار دم قبل وربما أثناء علاجك بعقار توليب للتنبؤ باحتمالية إصابتك بآثار جانبية متعلقة بالعضلات. من المعروف زيادة احتمالية الإصابة بآثار جانبية ذات صلة بالعضلات، مثل انحلال الربيدات، عند تناوُل أدوية معينة بالتَّزامن (انظر قسم: 2 &quot;تناوُل أدوية أخرى مع عقار توليب&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي الخاص بك أيضًا إذا كنت تُعاني من ضعف عضلي مستمر. قد يستلزم الأمر إجراء اختبارات إضافية وتناوُل أدوية إضافية لتشخيص هذه الحالة وعلاجها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من مرض السكري أو معرضًا للإصابة به، فسيقوم طبيبك بمتابعتك عن كثب أثناء الفترة التي تتناول فيها هذا الدَّواء. من المرجح أن تكون معرضًا لخطر الإصابة بمرض السكري إذا كنت تعاني من ارتفاع</p><p>&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; مستويات السكر والدهون في الدَّم وكنت تعاني من زيادة في الوزن ومن ارتفاع ضغط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناوُل أدوية أخرى مع عقار توليب</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى. هناك بعض الأدوية التي قد تغير من تأثير عقار توليب أو قد يغير عقار توليب من تأثيرها. قد يُؤدي هذا النوع من التداخل الدَّوائي إلى جعل أحد الدَّوائين أو كليهما أقل فعَّالية. وبدلًا من ذلك، يُمكن أن يُزيد من خطر الإصابة بآثار جانبية أو يزيد من شدتها، بما في ذلك حالة الهزال العضلي المهمة المعروفة باسم انحلال الربيدات المُبيَّنة في قسم 4:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستَخدَم لتغيير طريقة عمل جهازك المناعي، مثل: سيكلوسبورين.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المضادات الحيوية أو مضادات الفطريات، على سبيل المثال: إريثروميسين، كلاريثروميسين، تيليثروميسين، كيتوكونازول، إتراكونازول، فوريكونازول، فلوكونازول، پوساکونازول، ريفامبين.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى التي تُستَخدَم لتنظيم مستويات الدهون، على سبيل المثال: جيمفيبروزيل، الفيبرات الأخرى، كوليستيبول.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض حاصرات قنوات الكالسيوم التي تُستَخدَم لعلاج الذبحة الصدرية أو ارتفاع ضغط الدَّم، على سبيل المثال: أملوديبين، ديلتِيازِيم؛ كذلك الأدوية التي تعمل على تنظيم النَّظْم القلبي لديك، على سبيل المثال: ديجوكسِين، فيراباميل، أميودارون</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستَخدَم لعلاج فيروس نقص المناعة البشري، على سبيل المثال: ريتونافير، لوبينافير، أتازانافير، إندينافير، دارونافير، التَّركيبة المُكَوَّنة من تيبرانافير/ ريتونافير، وما إلى ذلك.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي تُستَخدَم في علاج التهاب الكبد من النوع &quot;سي&quot;، على سبيل المثال: تيلابريفير، بوسيبريفير والتركيبة المُكوَّنة من إلباسفير/ جرازوبريفير.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى المعروف عنها تداخلها مع عقار توليب تشمل إزيتيميب (والذي يخفض الكوليسترول)، وارفارين (والذي يقلل من تجلُّط الدَّم)، موانع الحَمْل الفموية، ستيريبنتول (مضاد للاختلاجات لعلاج الصرع)، سيميتيدين (يُستَخدَم لعلاج الحموضة والقُرَح الهضمية)، فينازون (مُسَكِّن)، كُولْشيسين (يُستَخدَم لعلاج النّقْرِس)، ومضادات الحموضة (مستحضرات علاج عُسْر الهضم التي تحتوي على الألومنيوم أو الماغنسيوم).</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي يتم الحصول عليها بدون وصفة طبية: نبتة سانت جونز</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا احتجت إلى تناوُل حمض الفوسيديك عن طريق الفم لعلاج عدوى بكتيرية فسيكون عليك التوقف مؤقتًا عن استخدام هذا الدَّواء</strong><strong>. </strong><strong>سيخبرك طبيبك بالوقت الذي يكون فيه من الآمن إعادة بدء العلاج بعقار توليب</strong><strong>.</strong> <strong>في حالات نادرة، قد يُؤدي تناوُل عقار توليب مع حمض الفوسيديك إلى ضعف أو ألم العضلات أو وجود ألمٍ بها عند الضغط عليها </strong><strong>(</strong><strong>انحلال الربيدات</strong><strong>).</strong> <strong>للاطلاع على المزيد من المعلومات بشأن انحلال الربيدات انظر قسم </strong><strong>4.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>استخدام عقار توليب مع الأطعمة والمشروبات والكحوليات</strong></p><p dir="RTL">انظر قسم 3 للاطلاع على تعليمات حول كيفية تناوُل عقار توليب. يُرجى ملاحظة ما يلي:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>عصير الجريب فروت</em><em>.</em></p><p dir="RTL">لا تتناول أكثر من كوب واحد صغير أو كوبين صغيرين من عصير الجريب فروت في اليوم؛ لأنَّ تناوُل كميات كبيرة منه قد يُغيِّر من تأثيرات عقار توليب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الكحوليات</em></p><p dir="RTL">تجنَّب شرب كمية أكثر مما يجب من الكحوليات أثناء تناوُل هذا الدَّواء. انظر قسم 2 &quot;تحذيرات واحتياطات&quot; للاطلاع على التَّفاصيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا تتناولي عقار توليب إذا كنتِ حاملًا، أو إذا كنتِ تحاولين الإنجاب. لا تتناولي عقار توليب إذا كان لديكِ القدرة على الحَمْل إلا إذا كنتِ تتبعين تدابير موثوقة لمنع الحَمْل.</p><p dir="RTL">لا تتناولي عقار توليب إذا كنتِ تُرضِعِين طبيعيًّا.</p><p dir="RTL">لم يتم بعد إثبات أمان عقار توليب أثناء الحَمْل والرضاعة الطبيعية. استشيري طبيبكِ أو الصيدلي الخاص بكِ قبل تناوُلِ أي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">عادةً لا يُؤثر هذا الدَّواء في قدرتك على قيادة المركبات أو تشغيل الآلات. لكن إذا كان هذا العقار يُؤثر على قدرتك على القيادة، لا تمارس القيادة. لا تستخدم أي أدوات أو آلات إذا تأثرت قدرتك على استخدامها بفعل هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي عقار توليب على الصوديوم. ويحتوي العقار على أقل من 1 مللي مول من الصوديوم (23 مجم) في كل قرص مغلف، وهذا يعني أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قبل بدء العلاج، سيخضعك طبيبك إلى نظام غذائي منخفض الكوليسترول، وهو ما عليك الاستمرار عليه أيضًا أثناء العلاج بعقار توليب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">جرعة البدء المُعتادة من عقار توليب هي 10 مجم مرة واحدة يوميًّا في البالغين والأطفال بعُمْر 10 أعوام أو أكثر. يُمكِن زيادة هذه الجرعة إذا اقتضى الأمر من قِبَل طبيبك حتى تتناول الكمية التي تحتاجها. سيعدل طبيبك الجرعة على فواصل زمنية قدرها 4 أسابيع أو أكثر. الجرعة القصوى من عقار توليب هي 80 مجم مرة واحدة يوميًّا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ابتلاع أقراص عقار توليب كاملةً مع شربة ماء، ويُمكِن تناوُلها في أي وقت من اليوم، مع الطعام أو بدونه. مع ذلك، حاول أن تتناول القرص الخاص بك في نفس الوقت من كل يوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناول دائمًا هذا الدَّواء بالضبط كما أخبرك طبيبك أو الصيدلي الخاص بك. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحدد طبيبك مدة العلاج بعقار توليب</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يُرجى استشارة طبيبك إذا كنت تعتقد أن تأثير عقار توليب أقوى مما يجب أو أضعف مما يجب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت كمية أكثر مما يجب من عقار توليب</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا تناولت بطريق الخطأ كمية أكبر مما يجب من أقراص عقار توليب (أكثر من جرعتك اليومية المُعتادة)، فاتصل بطبيبك أو أقرب مستشفى؛ للحصول على المشورة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أغفلت تناوُل عقار توليب</strong></p><p dir="RTL">إذا أغفلت تناوُل جرعة، فما عليك سوى تناوُل جرعتك المُقَررة التَّالية في الوقت الصحيح. لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناوُل عقار توليب</strong></p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء أو كنت ترغب في إيقاف علاجك، فاستشر طبيبك أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تعرَّضت لأي من الآثار الجانبية أو الأعراض الخطيرة التَّالية، فتوقف عن تناوُل أقراصك وأخبِر طبيبك فورًا أو اذهب إلى أقرب قسم حوادث وطوارئ بأحد المستشفيات</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">نادرة : قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية خطيرة تسبب تورمًا في الوجه واللسان والحَلْق وهو ما قد يُؤدي إلى صعوبة كبيرة في التنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض خطير مصحوب بحالة شديدة من تقشُّر الجلد وتورُّمه وظهور بثور على الجلد والفم والعينين والأعضاء التَّناسلية وحُمّى. طفح جلدي يتسم ببقع ذات لون أحمر مائل إلى الوردي لا سيما على راحتي اليدين أو باطن القدمين والذين قد يظهر بهما نفطات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف أو ألم العضلات أو ألم عند الضغط عليها أو تمزُّق عضلي أو تغيُّر لون البول إلى اللون الأحمر المائل إلى البني، ولا سيَّما إذا شعرت في الوقت نفسه بالتَّوعُّك أو عانيت من ارتفاعٍ بدرجة الحرارة، فقد يكون ذلك ناجمًا عن حدوث تحلل عضلي غير طبيعي (انحلال الربيدات). لا يشفى التحلل العضلي غير الطبيعي دائمًا، حتى بعد توقفك عن تناوُل أتورفاستاتين، وقد يكون مُهَدِّدًا للحياة ويُؤدي إلى مشاكل بالكُلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرة جدًّا: قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10000 شخص:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعرَّضت لمشاكل مصحوبة بحالة غير متوقعة أو غير معتادة من النزيف أو التكدُّم، التعب، فقدان الشهية، ألم المعدة، شعور بالإعياء، اصفرار الجلد أو العينين (يرقان)، فقد يُشير ذلك إلى وجود شكوى متعلقة بالكبد. عليك استشارة طبيبك في أسرع وقت ممكن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة شبيهة بالذئبة (بما في ذلك الطفح الجلدي، اضطرابات المفاصل، والتأثيرات على خلايا الدَّم).</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية المحتملة الأخرى مع عقار توليب</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الممرات الأنفية، ألم في الحَلْق، نزيف من الأنف.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاعات بمستويات السُّكر بالدَّم (إذا كنت مصابًا بمرض السُّكَّرِيّ، فاستمر في مراقبة مستويات السُّكَّر في دمك بعناية)، ارتفاع مستوى كيناز الكرياتين في الدَّم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان، إمساك، ريح، عسر هضم، إسهال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمفاصل، تورُّم بالمفاصل، ألم بالعضلات، تقلصات عضلية وألم بالظهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج اختبارات الدَّم التي تُظهِر أن وظائف الكبد لديك قد تصبح غير طبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية، زيادة الوزن، انخفاضات بمستويات السكر في الدَّم (إذا كنت مصابًا بداء السكري، عليك الاستمرار في متابعة مستويات السكر في الدَّم لديك بعناية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كوابيس، أرق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار، تنميل أو وخز في أصابع اليدين والقدمين، ضعف الإحساس بالألم أو اللمس، تغيرات في حاسة التذوق، فقدان الذاكرة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طنين بالأذنين و/ أو الرأس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء، تجشؤ، ألم في الجزء العلوي والسفلي من البطن، التهاب البنكرياس (التهاب البنكرياس الذي يؤدي إلى ألم بالمعدة).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، طفح جلدي وحكة، شرى (أرتكاريا)، تساقط الشعر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالرقبة، إرهاق عضلي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرهاق، شعور بالتوعُّك، ضعف، ألم بالصدر، تورُّم خاصةً في الكاحلين (وذمة)، ارتفاع درجة الحرارة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج اختبارات البول التي تُشير إلى وجود خلايا دم بيضاء بالبول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الرؤية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف أو كدمات غير متوقعة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ركود صفراوي (اصفرار الجلد وبياض العينين).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابة بالأوتار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرة جدًّا (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10000 شخص):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية -قد تشمل الأعراض أزيزًا مفاجئًا وألمًا أو ضيقًا بالصدر، تورم جفون العينين، أو الوجه أو الشفتين أو الفم أو اللسان أو الحلق، صعوبة التَّنفس، هبوطًا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان السمع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تثدّي الرجال (تضخم الثدي لدى الرجال).</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير معروفة (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة):</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف عضلي مستمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية المُحتمَلة التي تم الإبلاغ عنها مع بعض الستاتينات (أدوية من نفس النوع):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات جنسية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في التنفس تتضمن سعالًا مستمرًّا و/أو ضيقًا بالتنفس أو حمى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض السُّكَّرِي. من المرجح حدوث ذلك إذا كنت تعاني من ارتفاع مستويات السكر والدهون في الدَّم وكنت تعاني من زيادة الوزن وارتفاع ضغط الدَّم. سيقوم طبيبك بمراقبتك أثناء الفترة التي تتناول فيها هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى طبيبك أو الصيدلي الخاص بك. يشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة. بإبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول أمان هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية والشريط بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; لا يخزن في درجة حرارة تتعدى 30 درجة مئوية.</p><p dir="RTL">&nbsp;&nbsp;&nbsp; يجب حفظ الدواء في العبوة الأصلية لحمايته من الرطوبة.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعَّالة هي أتورفاستاتين (في هيئة ملح الكالسيوم).</p><p dir="RTL">يحتوي كل قرص مُغَلَّف على 10 مجم أتورفاستاتين (في هيئة ملح الكالسيوم). يحتوي كل قرص مُغَلَّف على 20 مجم أتورفاستاتين (في هيئة ملح الكالسيوم). يحتوي كل قرص مُغَلَّف على 40 مجم أتورفاستاتين (في هيئة ملح الكالسيوم). يحتوي كل قرص مُغَلَّف على 80 مجم أتورفاستاتين (في هيئة ملح الكالسيوم).</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي لوريل سلفات الصوديوم، سليلوز دقيق التَّبلور، سيليكا غروية غير مائية، نشا الذرة سابق التجلتُّن، تروميتامول، أكسيد الحديد الأصفر (E 172)، ستيرات الماغنسيوم، تلك، جليكولات نشا الصوديوم (النوع &quot;أ&quot;)، صوديوم كارميلوز، جليسيرول وهيدروكسي إيثيل السليلوز.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الأقراص المُغلَّفة 10 مجم:</p><p dir="RTL">أقراص مغلَّفة ذات لون أصفر فاتح، مُبَرْقَشة، لامعة، دائرية، ثنائية التحدُّب، محفور على أحد وجهيها &quot;HLA 10&quot; وقياس قطرها 7.2 مللي متر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأقراص المُغلَّفة 20 مجم:</p><p dir="RTL">أقراص مغلَّفة ذات لون أصفر فاتح، مُبَرْقَشة، لامعة، دائرية، ثنائية التحدُّب، محفور على أحد وجهيها &quot;HLA 20&quot; وقياس قطرها 9.2 مللي متر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأقراص المُغلَّفة 40 مجم:</p><p dir="RTL">أقراص مغلَّفة ذات لون أصفر فاتح، مُبَرْقَشة، لامعة، دائرية، ثنائية التحدُّب، محفور على أحد وجهيها &quot;HLA 40&quot; وقياس قطرها 11.2 مللي متر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأقراص المُغلَّفة 80 مجم:</p><p dir="RTL">أقراص مغلَّفة ذات لون أصفر فاتح، مُبَرْقَشة، لامعة، بيضاوية، ثنائية التحدُّب، محفور على أحد وجهيها &quot;HLA 80&quot; ويبلغ طولها 19.3 مللي متر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأقراص المغلفة معبأة في شرائط من الألومنيوم/ الألومنيوم بداخل حافظة كرتونية.</p><p dir="RTL"><em>[</em><em>AT/H/0305 10 mg</em><em>]</em></p><p dir="RTL">أحجام العبوات: 7 و14 و28 و30 و56 و60 و63 و90 و91 و100 قرص مغلف</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>[</em><em>AT/H/0305 20 mg</em><em>]</em></p><p dir="RTL">أحجام العبوات: 7 و14 و28 و30 و56 و60 و63 و90 و91 و100 قرص مغلف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>[</em><em>AT/H/0305 40 mg</em><em>]</em></p><p dir="RTL">أحجام العبوات: 7 و14 و28 و30 و56 و60 و63 و90 و91 و100 قرص مغلف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>[</em><em>AT/H/0305 80 mg</em><em>]</em></p><p dir="RTL">أحجام العبوات: 7 و28 و30 و50 و60 و90 و98 و100 قرص مغلف.</p><p dir="RTL"><em>[</em><em>AT/H/0308 10 mg, 20 mg, 40 mg, 80 mg</em><em>]</em></p><p dir="RTL">أحجام العبوات: 7 و10 و14 و20 و21 و28 و30 و35 و42 و49 و50 و56 و60 و63 و70 و77 و84 و90 و91 و98 و100 قرص</p><p dir="RTL">&nbsp;مغلف.</p><p dir="RTL">&nbsp;</p><p>قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;شركة ليك للأدوية شركة مساهمة</p><p dir="RTL">&nbsp;ليوبليانا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            09/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tulip 10 mg film-coated tablets 
Tulip 20 mg film-coated 
Tulip 40 mg film-coated tablets 
Tulip 80 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 10 mg of atorvastatin (as calcium salt). Excipient with known effect
Each film-coated tablet contains up to 1.52 mg of sodium.

Each film-coated tablet contains 20 mg of atorvastatin (as calcium salt).

Excipient with known effect
Each film-coated tablet contains up to 2.55 mg of sodium.

Each film-coated tablet contains 40 mg of atorvastatin (as calcium salt).

Excipient with known effect
Each film-coated tablet contains up to 4.30 mg of sodium. 

Each film-coated tablet contains 80 mg of atorvastatin (as calcium salt).

Excipient with known effect
Each film-coated tablet contains up to 8.01 mg of sodium.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.

Tulip 10 mg film-coated tablets:
Light yellow, dappled, glossy, round biconvex film-coated tablets, debossed with “HLA 10” on one side measuring 7,2 mm in diameter
Tulip 20 mg film-coated tablets: Light yellow, dappled, glossy, round biconvex film-coated tablets, debossed with “HLA 20” on one side measuring 9,2 mm in diameter
Tulip 40 mg film-coated tablets: Light yellow, dappled, glossy, round biconvex film-coated tablets, debossed with “HLA 40” on one side measuring 11,2 mm in diameter
Tulip 80 mg film-coated tablets: Light yellow, dappled, glossy, oval biconvex film-coated tablets, debossed with “HLA 80” on one side measuring 19,3 mm in length

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Hypercholesterolaemia</u></em></p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p>Tulip is indicated as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (Corresponding to Types IIa and IIb of the Fredrickson classification) when response to diet and other nonpharmacological measures is inadequate.</p><p>Tulip is also indicated to reduce total-C and LDL-C in adults with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.</p><p>&nbsp;</p><p><em><u>Prevention of cardiovascular disease</u></em></p><p><em>&nbsp;</em></p><p>Prevention of cardiovascular events in adult patients estimated to have a high risk for a first cardiovascular event (see section 5.1), as an adjunct to correction of other risk factors.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>The patient should be placed on a standard cholesterol-lowering diet before receiving Tulip and should continue on this diet during treatment with Tulip.</p><p>The dose should be individualised according to baseline LDL-C levels, the goal of therapy, and patient response.</p><p>The usual starting dose is 10 mg once a day. Adjustment of dose should be made at intervals of 4 weeks or more. The maximum dose is 80 mg once a day.</p><p>&nbsp;</p><p><u>Primary hypercholesterolaemia and combined (mixed) hyperlipidaemia</u></p><p>&nbsp;</p><p>The majority of patients are controlled with Tulip 10 mg once a day. A therapeutic response is evident within 2 weeks, and the maximum therapeutic response is usually achieved within 4 weeks. The response is maintained during chronic therapy.</p><p>&nbsp;</p><p><u>Heterozygous familial hypercholesterolaemia</u></p><p>&nbsp;</p><p>Patients should be started with Tulip 10 mg daily. Doses should be individualised and adjusted every 4 weeks to 40 mg daily. Thereafter, either the dose may be increased to a maximum of 80 mg daily or a bile acid sequestrant may be combined with 40 mg atorvastatin once daily.</p><p>&nbsp;</p><p><u>Homozygous familial hypercholesterolaemia</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Only limited data are available (see section 5.1).</p><p>&nbsp;</p><p>&nbsp;</p><p>The dose of atorvastatin in patients with homozygous familial hypercholesterolaemia is 10 to 80 mg daily (see section 5.1). Atorvastatin should be used as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) in these patients or if such treatments are unavailable.</p><p>&nbsp;</p><p><u>Prevention of cardiovascular disease</u></p><p>&nbsp;</p><p>In the primary prevention trials the dose was 10 mg/day. Higher doses may be necessary in order to attain (LDL-) cholesterol levels according to current guidelines.</p><p>&nbsp;</p><p><u>Co-administration with other medicinal products</u></p><p>&nbsp;</p><p>In patients taking hepatitis C antiviral agents elbasvir/grazoprevir concomitantly with atorvastatin, the dose of atorvastatin should not exceed 20 mg/day (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>No adjustment of dose is required (see section 4.4). <u>Hepatic impairment</u></p><p>&nbsp;</p><p>Tulip should be used with caution in patients with hepatic impairment (see sections 4.4 and 5.2). Tulip is contraindicated in patients with active liver disease (see section 4.3).</p><p>&nbsp;</p><p><u>Elderly</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Efficacy and safety in patients older than 70 using recommended doses are similar to those seen in the general population.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p><em>Hypercholesterolaemia:</em></p><p><em>&nbsp;</em></p><p>Paediatric use should only be carried out by physicians experienced in the treatment of paediatric hyperlipidaemia and patients should be re-evaluated on a regular basis to assess progress.</p><p>&nbsp;</p><p>For patients with Heterozygous Familial Hypercholesterolemia aged 10 years and above, the recommended starting dose of atorvastatin is 10 mg per day (see section 5.1). The dose may be increased to 80 mg daily, according to the response and tolerability. Doses should be individualised according to the recommended goal of therapy.</p><p>Adjustments should be made at intervals of 4 weeks or more. The dose titration to 80 mg daily is supported by study data in adults and by limited clinical data from studies in children with Heterozygous Familial Hypercholesterolemia (see sections 4.8 and 5.1).</p><p>&nbsp;</p><p>&nbsp;</p><p>There are limited safety and efficacy data available in children with Heterozygous Familial Hypercholesterolemia between 6 to 10 years of age derived from open-label studies. Atorvastatin is not indicated in the treatment of patients below the age of 10 years. Currently available data are described in sections 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.</p><p>&nbsp;</p><p>Other pharmaceutical forms/strengths may be more appropriate for this population. <u>Method of administration</u></p><p>Tulip is for oral administration. Each daily dose of atorvastatin is given all at once and may be given at any time of day with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tulip is contraindicated in patients:
	with hypersensitivity to the active substance or to any of the excipients listed in section 6.1
	with active liver disease or unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal
	during pregnancy, while breast-feeding and in women of child-bearing potential not using appropriate contraceptive measures (see section 4.6)
	treated with the hepatitis C antivirals glecaprevir/pibrentasvir.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Liver effects</u></p><p>&nbsp;</p><p>Liver function tests should be performed before the initiation of treatment and periodically thereafter. Patients who develop any signs or symptoms suggestive of liver injury should have liver function tests performed. Patients who develop increased transaminase levels should be monitored until the abnormality(ies) resolve. Should an increase in transaminases of greater than 3 times the upper limit of normal (ULN) persist, reduction of dose or withdrawal of Tulip is recommended (see section 4.8).</p><p>Tulip should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease.</p><p>&nbsp;</p><p><u>Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)</u></p><p>&nbsp;</p><p>In a post-hoc analysis of stroke subtypes in patients without coronary heart disease (CHD) who had a recent stroke or transient ischaemic attack (TIA) there was a higher incidence of haemorrhagic stroke in patients initiated on atorvastatin 80 mg compared to placebo. The increased risk was particularly noted in patients with prior haemorrhagic stroke or lacunar infarct at study entry. For patients with prior haemorrhagic stroke or lacunar infarct, the balance of risks and benefits of atorvastatin 80 mg is</p><p>&nbsp;</p><p>&nbsp;</p><p>uncertain, and the potential risk of haemorrhagic stroke should be carefully considered before initiating treatment (see section 5.1).</p><p>&nbsp;</p><p><u>Skeletal muscle effects</u></p><p>&nbsp;</p><p>Atorvastatin, like other HMG-CoA reductase inhibitors, may in rare occasions affect the skeletal muscle and cause myalgia, myositis, and myopathy that may progress to rhabdomyolysis, a potentially life-threatening condition characterised by markedly elevated creatine kinase (CK) levels (&gt; 10 times ULN), myoglobinaemia and myoglobinuria which may lead to renal failure.</p><p>&nbsp;</p><p>There have been very rare reports of an immune-mediated necrotising myopathy (IMNM) during or after treatment with some statins. IMNM is clinically characterised by persistent proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment.</p><p>&nbsp;</p><p><em><u>Before the treatment</u></em></p><p><em>&nbsp;</em></p><p>Atorvastatin should be prescribed with caution in patients with pre-disposing factors for rhabdomyolysis. A CK level should be measured before starting statin treatment in the following situations:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal impairment</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypothyroidism</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Personal or familial history of hereditary muscular disorders</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Previous history of muscular toxicity with a statin or fibrate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Previous history of liver disease and/or where substantial quantities of alcohol are consumed</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In elderly (age &gt; 70 years), the necessity of such measurement should be considered, according to the presence of other predisposing factors for rhabdomyolysis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Situations where an increase in plasma levels may occur, such as interactions (see section 4.5) and special populations including genetic subpopulations (see section 5.2)</p><p>&nbsp;</p><p>In such situations, the risk of treatment should be considered in relation to possible benefit, and clinical monitoring is recommended.</p><p>If CK levels are significantly elevated (&gt; 5 times ULN) at baseline, treatment should not be started.</p><p>&nbsp;</p><p><em><u>Creatine kinase measurement</u></em></p><p><em>&nbsp;</em></p><p>Creatine kinase (CK) should not be measured following strenuous exercise or in the presence of any plausible alternative cause of CK increase as this makes value interpretation difficult. If CK levels are significantly elevated at baseline (&gt; 5 times ULN), levels should be remeasured within 5 to 7 days later to confirm the results.</p><p>&nbsp;</p><p><em><u>Whilst on treatment</u></em></p><p>&nbsp;</p><p><em>&nbsp;</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients must be asked to promptly report muscle pain, cramps, or weakness especially if accompanied by malaise or fever.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If such symptoms occur whilst a patient is receiving treatment with atorvastatin, their CK levels should be measured. If these levels are found to be significantly elevated (&gt; 5 times ULN), treatment should be stopped.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If muscular symptoms are severe and cause daily discomfort, even if the CK levels are elevated to &le; 5 x ULN, treatment discontinuation should be considered.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If symptoms resolve and CK levels return to normal, then re-introduction of atorvastatin or introduction of an alternative statin may be considered at the lowest dose and with close monitoring.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atorvastatin must be discontinued if clinically significant elevation of CK levels (&gt; 10 x ULN) occur, or if rhabdomyolysis is diagnosed or suspected.</p><p>&nbsp;</p><p><em><u>Concomitant treatment with other medicinal products</u></em></p><p><em>&nbsp;</em></p><p>Risk of rhabdomyolysis is increased when atorvastatin is administered concomitantly with certain medicinal products that may increase the plasma concentration of atorvastatin such as potent inhibitors of CYP3A4 or transport proteins (e.g. ciclosporine, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole and HIV protease inhibitors including ritonavir, lopinavir, atazanavir, indinavir, darunavir, tipranavir/ritonavir, etc). The risk of myopathy may also be increased with the concomitant use of gemfibrozil and other fibric acid derivates, antivirals for the treatment of hepatitis C (HCV) (boceprevir, telaprevir, elbasvir/grazoprevir), erythromycin, niacin, or ezetimibe. If possible, alternative (non-interacting) therapies should be considered instead of these medicinal products.</p><p>&nbsp;</p><p>In cases where co-administration of these medicinal products with atorvastatin is necessary, the benefit and the risk of concurrent treatment should be carefully considered. When patients are receiving medicinal products that increase the plasma concentration of atorvastatin, a lower maximum dose of atorvastatin is recommended. In addition, in the case of potent CYP3A4 inhibitors, a lower starting dose of atorvastatin should be considered and appropriate clinical monitoring of these patients is recommended (see section 4.5).</p><p>&nbsp;</p><p>Atorvastatin must not be co-administered with systemic formulations of fusidic acid or within 7 days of stopping fusidic acid treatment. In patients where the use of systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of fusidic acid treatment. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving fusidic acid and statins in combination (see section 4.5). The patient should be advised to seek medical advice immediately if they experience any symptoms of muscle weakness, pain or tenderness.</p><p>&nbsp;</p><p>Statin therapy may be re-introduced seven days after the last dose of fusidic acid.</p><p>&nbsp;</p><p>&nbsp;</p><p>In exceptional circumstances, where prolonged systemic fusidic acid is needed, e.g., for the treatment of severe infections, the need for co-administration of Tulip and fusidic acid should only be considered on a case by case basis and under close medical supervision.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>No clinically significant effect on growth and sexual maturation was observed in a 3-year study based on the assessment of overall maturation and development, assessment of Tanner Stage, and measurement of height and weight (see section 4.8).</p><p>&nbsp;</p><p><u>Interstitial lung disease</u></p><p>&nbsp;</p><p>Exceptional cases of interstitial lung disease have been reported with some statins, especially with long term therapy (see section 4.8). Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued.</p><p>&nbsp;</p><p><u>Diabetes Mellitus</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Some evidence suggests that statins as a class raise blood glucose and in some patients, at high risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is appropriate.</p><p>This risk, however, is outweighed by the reduction in vascular risk with statins and therefore should not be a reason for stopping statin treatment. Patients at risk (fasting glucose 5.6 to 6.9 mmol/L, BMI&gt;30kg/m2, raised triglycerides, hypertension) should be monitored both clinically and biochemically according to national guidelines.</p><p>&nbsp;</p><p>Tulip contains sodium. It contains less than 1 mmol sodium (23 mg) per film- coated tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effect of co-administered medicinal products on atorvastatin</u></p><p>&nbsp;</p><p>Atorvastatin is metabolised by cytochrome P450 3A4 (CYP3A4) and is a substrate of the hepatic transporters, organic anion-transporting polypeptide 1B1 (OATP1B1) and 1B3 (OATP1B3) transporter. Metabolites of atorvastatin are substrates of OATP1B1. Atorvastatin is also identified as a substrate of the multi-drug resistance protein 1 (MDR1) and breast cancer resistance protein (BCRP), which may limit the intestinal absorption and biliary clearance of atorvastatin (see section 5.2). Concomitant administration of medicinal products that are inhibitors of CYP3A4 or transport proteins may lead to increased plasma concentrations of atorvastatin and an increased risk of myopathy. The risk might also be increased at concomitant administration of atorvastatin with other medicinal products that have a potential to induce myopathy, such as fibric acid derivates and ezetimibe (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>CYP3A4 inhibitors</u></em></p><p><em>&nbsp;</em></p><p>Potent CYP3A4 inhibitors have been shown to lead to markedly increased concentrations of atorvastatin (see Table 1 and specific information below). Co-administration of potent CYP3A4 inhibitors (e.g. ciclosporin, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole, some antivirals used in the treatement of HCV (e.g. elbasvir/grazoprevir) and HIV protease inhibitors including ritonavir, lopinavir, atazanavir, indinavir, darunavir, etc.) should be avoided if possible. In cases where co-administration of these medicinal products with atorvastatin cannot be avoided lower starting and maximum doses of atorvastatin should be considered and appropriate clinical monitoring of the patient is recommended (see Table 1).</p><p>&nbsp;</p><p>Moderate CYP3A4 inhibitors (e.g. erythromycin, diltiazem, verapamil and fluconazole) may increase plasma concentrations of atorvastatin (see Table 1). An increased risk of myopathy has been observed with the use of erythromycin in combination with statins. Interaction studies evaluating the effects of amiodarone or verapamil on atorvastatin have not been conducted. Both amiodarone and verapamil are known to inhibit CYP3A4 activity and co-administration with atorvastatin may result in increased exposure to atorvastatin. Therefore, a lower maximum dose of atorvastatin should be considered and appropriate clinical monitoring of the patient is recommended when concomitantly used with moderate CYP3A4 inhibitors. Appropriate clinical monitoring is recommended after initiation or following dose adjustments of the inhibitor.</p><p>&nbsp;</p><p><em><u>CYP3A4 inducers</u></em></p><p><em>&nbsp;</em></p><p>Concomitant administration of atorvastatin with inducers of cytochrome P450 3A (e.g. efavirenz, rifampin, St. John&rsquo;s Wort) can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual interaction mechanism of rifampin, (cytochrome P450 3A induction and inhibition of hepatocyte uptake transporter OATP1B1), simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. The effect of rifampin on atorvastatin concentrations in hepatocytes is, however, unknown and if concomitant administration cannot be avoided, patients should be carefully monitored for efficacy.</p><p>&nbsp;</p><p><em><u>Transport inhibitors</u></em></p><p><em>&nbsp;</em></p><p>Inhibitors of transport proteins (e.g. ciclosporin) can increase the systemic exposure of atorvastatin (see Table 1). The effect of inhibition of hepatic uptake transporters on atorvastatin concentrations in hepatocytes is unknown. If concomitant administration cannot be avoided, a dose reduction and clinical monitoring for efficacy is recommended (see Table 1).</p><p>&nbsp;</p><p><em><u>Gemfibrozil / fibric acid derivatives</u></em></p><p><em>&nbsp;</em></p><p>The use of fibrates alone is occasionally associated with muscle related events, including rhabdomyolysis. The risk of these events may be increased with the concomitant use of fibric acid</p><p>&nbsp;</p><p>&nbsp;</p><p>derivatives and atorvastatin. If concomitant administration cannot be avoided, the lowest dose of atorvastatin to achieve the therapeutic objective should be used and the patients should be appropriately monitored (see section 4.4).</p><p>&nbsp;</p><p><em><u>Ezetimibe</u></em></p><p><em>&nbsp;</em></p><p>The use of ezetimibe alone is associated with muscle related events, including rhabdomyolysis. The risk of these events may therefore be increased with concomitant use of ezetimibe and atorvastatin. Appropriate clinical monitoring of these patients is recommended.</p><p>&nbsp;</p><p><em><u>Colestipol</u></em></p><p><em>&nbsp;</em></p><p>Plasma concentrations of atorvastatin and its active metabolites were lower (ratio of atorvastatin concentration: 0.74) when colestipol was co-administered with atorvastatin. However, lipid effects were greater when atorvastatin and colestipol were co-administered than when either medicinal product was given alone.</p><p>&nbsp;</p><p><em><u>Fusidic acid</u></em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p>The risk of myopathy including rhabdomyolysis may be increased by the concomitant administration of systemic fusidic acid with statins. The mechanism of this interaction (whether it is pharmacodynamic or pharmacokinetic, or both) is yet unknown. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination.</p><p>If treatment with systemic fusidic acid is necessary, atorvastatin treatment should be discontinued throughout the duration of the fusidic acid treatment. Also see section 4.4.</p><p>&nbsp;</p><p><em><u>Colchicine</u></em></p><p><em>&nbsp;</em></p><p>Although interaction studies with atorvastatin and colchicine have not been conducted, cases of myopathy have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine.</p><p>&nbsp;</p><p><u>Effect of atorvastatin on co-administered medicinal products</u></p><p>&nbsp;</p><p><em><u>Digoxin</u></em></p><p><em>&nbsp;</em></p><p>When multiple doses of digoxin and 10 mg atorvastatin were co-administered, steady-state digoxin concentrations increased slightly. Patients taking digoxin should be monitored appropriately.</p><p>&nbsp;</p><p><em><u>Oral contraceptives</u></em></p><p><em>&nbsp;</em></p><p>Co-administration of atorvastatin with an oral contraceptive produced increases in plasma concentrations of norethindrone and ethinyl oestradiol.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Warfarin</u></em></p><p><em>&nbsp;</em></p><p>In a clinical study in patients receiving chronic warfarin therapy, co-administration of atorvastatin 80 mg daily with warfarin caused a small decrease of about 1.7 seconds in prothrombin time during</p><p>the first 4 days of dosing which returned to normal within 15 days of atorvastatin treatment. Although only very rare cases of clinically significant anticoagulant interactions have been reported, prothrombin time should be determined before starting atorvastatin in patients taking coumarin anticoagulants and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs. Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants. If the dose of atorvastatin is changed or discontinued, the same procedure should be repeated. Atorvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Drug-drug interaction studies have only been performed in adults. The extent of interactions in the paediatric population is not known. The above mentioned interactions for adults and the warnings in section 4.4 should be taken into account for the paediatric population.</p><p>&nbsp;</p><p><u>Drug interaction</u></p><p>&nbsp;</p><p>Table 1: Effect of co-administered medicinal products on the pharmacokinetics of atorvastatin</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Co-administered medicinal product</p><p>and dosing regimen</p></td><td colspan="3" style="vertical-align:top"><p>Atorvastatin</p></td></tr><tr><td style="vertical-align:top"><p>Dose (mg)</p></td><td style="vertical-align:top"><p>Ratio of AUC&amp;</p></td><td style="vertical-align:top"><p>Clinical Recommendation#</p></td></tr><tr><td style="vertical-align:top"><p>Tipranavir 500 mg BID/ Ritonavir 200 mg BID, 8 days</p><p>(days 14 to 21)</p></td><td style="vertical-align:top"><p>40 mg on day 1,</p><p>10 mg on day 20</p></td><td style="vertical-align:top"><p>9.4</p></td><td rowspan="3" style="vertical-align:top"><p>In cases where co- administration with atorvastatin is necessary, do not exceed 10 mg atorvastatin daily. Clinical monitoring of these patients is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Telaprevir 750 mg q8h, 10 days</p></td><td style="vertical-align:top"><p>20 mg, SD</p></td><td style="vertical-align:top"><p>7.9</p></td></tr><tr><td style="vertical-align:top"><p>Ciclosporin 5.2 mg/kg/day, stable dose</p></td><td style="vertical-align:top"><p>10 mg OD for 28 days</p></td><td style="vertical-align:top"><p>8.7</p></td></tr><tr><td style="vertical-align:top"><p>Glecaprevir 400 mg OD/ Pibrentasvir 120 mg OD, 7 days</p></td><td style="vertical-align:top"><p>10 mg OD for 7 days</p></td><td style="vertical-align:top"><p>8.3</p></td><td style="vertical-align:top"><p>Co-administration with products containing glecaprevir or pibrentasvir is contraindicated (see section 4.3).</p></td></tr><tr><td style="vertical-align:top"><p>Lopinavir 400 mg BID/ Ritonavir 100 mg BID, 14 days</p></td><td style="vertical-align:top"><p>20 mg OD for 4 days</p></td><td style="vertical-align:top"><p>5.9</p></td><td rowspan="2" style="vertical-align:top"><p>In cases where co- administration with atorvastatin is necessary, lower maintenance doses of atorvastatin are recommended. At atorvastatin</p></td></tr><tr><td style="vertical-align:top"><p>Clarithromycin 500 mg BID, 9 days</p></td><td style="vertical-align:top"><p>80 mg OD for 8 days</p></td><td style="vertical-align:top"><p>4.5</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>doses exceeding 20 mg, clinical monitoring of these patients is recommended<em>.</em></p></td></tr><tr><td style="vertical-align:top"><p>Saquinavir 400 mg BID/ Ritonavir (300 mg BID from days 5-7, increased to 400 mg</p><p>BID on day 8), days 4-18, 30 min after atorvastatin dosing</p></td><td style="vertical-align:top"><p>40 mg OD for 4 days</p></td><td style="vertical-align:top"><p>3.9</p></td><td rowspan="5" style="vertical-align:top"><p>In cases where co- administration with atorvastatin is necessary, lower maintenance doses of atorvastatin are recommended. At atorvastatin doses exceeding 40 mg, clinical monitoring of these patients is recommended<em>.</em></p></td></tr><tr><td style="vertical-align:top"><p>Darunavir 300 mg BID/ Ritonavir 100 mg BID, 9 days</p></td><td style="vertical-align:top"><p>10 mg OD for 4 days</p></td><td style="vertical-align:top"><p>3.4</p></td></tr><tr><td style="vertical-align:top"><p>Itraconazole 200 mg OD, 4 days</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>3.3</p></td></tr><tr><td style="vertical-align:top"><p>Fosamprenavir 700 mg BID/ Ritonavir 100 mg BID, 14 days</p></td><td style="vertical-align:top"><p>10 mg OD for 4 days</p></td><td style="vertical-align:top"><p>2.5</p></td></tr><tr><td style="vertical-align:top"><p>Fosamprenavir 1400 mg BID, 14 days</p></td><td style="vertical-align:top"><p>10 mg OD for 4 days</p></td><td style="vertical-align:top"><p>2.3</p></td></tr><tr><td style="vertical-align:top"><p>Nelfinavir 1250 mg BID, 14 days</p></td><td style="vertical-align:top"><p>10 mg OD for 28 days</p></td><td style="vertical-align:top"><p>1.74</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr><tr><td style="vertical-align:top"><p>Grapefruit juice, 240 mL OD*</p></td><td style="vertical-align:top"><p>40 mg, SD</p></td><td style="vertical-align:top"><p>1.37</p></td><td style="vertical-align:top"><p>Concomitant intake of large quantities of grapefruit juice and atorvastatin is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Diltiazem 240 mg OD, 28 days</p></td><td style="vertical-align:top"><p>40 mg, SD</p></td><td style="vertical-align:top"><p>1.51</p></td><td style="vertical-align:top"><p>After initiation or following dose adjustments of diltiazem, appropriate clinical monitoring of these patients is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Erythromycin 500 mg QID, 7 days</p></td><td style="vertical-align:top"><p>10 mg, SD</p></td><td style="vertical-align:top"><p>1.33</p></td><td style="vertical-align:top"><p>Lower maximum dose and clinical monitoring of these patients is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Amlodipine 10 mg, single dose</p></td><td style="vertical-align:top"><p>80 mg, SD</p></td><td style="vertical-align:top"><p>1.18</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr><tr><td style="vertical-align:top"><p>Cimetidine 300 mg QID, 2 weeks</p></td><td style="vertical-align:top"><p>10 mg OD for 2 weeks</p></td><td style="vertical-align:top"><p>1.00</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr><tr><td style="vertical-align:top"><p>Colestipol 10 g BID, 24 weeks</p></td><td style="vertical-align:top"><p>40 mg OD for 8 weeks</p></td><td style="vertical-align:top"><p>0.74**</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr><tr><td style="vertical-align:top"><p>Antacid suspension of magnesium and aluminium hydroxides, 30 mL QID, 17 days</p></td><td style="vertical-align:top"><p>10 mg OD for 15 days</p></td><td style="vertical-align:top"><p>0.66</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Efavirenz 600 mg OD, 14 days</p></td><td style="vertical-align:top"><p>10 mg for 3 days</p></td><td style="vertical-align:top"><p>0.59</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr><tr><td style="vertical-align:top"><p>Rifampin 600 mg OD, 7 days (co-administered)</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>1.12</p></td><td rowspan="2" style="vertical-align:top"><p>If co-administration cannot be avoided, simultaneous co- administration of atorvastatin with rifampin is recommended, with clinical monitoring.</p></td></tr><tr><td style="vertical-align:top"><p>Rifampin 600 mg OD, 5 days (doses separated)</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>0.20</p></td></tr><tr><td style="vertical-align:top"><p>Gemfibrozil 600 mg BID, 7 days</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>1.35</p></td><td style="vertical-align:top"><p>Lower starting dose and clinical monitoring of these patients is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Fenofibrate 160 mg OD, 7 days</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>1.03</p></td><td style="vertical-align:top"><p>Lower starting dose and clinical monitoring of these patients is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Boceprevir 800 mg TID, 7 days</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>Lower starting dose and clinical monitoring of these patients is recommended. The dose of atorvastatin should not exceed a daily dose of 20 mg during co- administration with boceprevir.</p></td></tr><tr><td style="vertical-align:top"><p>Elbasvir 50 mg OD/ Grazoprevir&nbsp; 200 mg OD, 13 days</p></td><td style="vertical-align:top"><p>10 mg SD</p></td><td style="vertical-align:top"><p>1.95</p></td><td style="vertical-align:top"><p>The dose of atorvastatin should not exceed a daily dose of 20 mg during co-administration with products containing elbasvir or grazoprevir.</p></td></tr></tbody></table><p>&nbsp;</p><p>&amp; Represents ratio of treatments (co-administered medicinal product plus atorvastatin versus atorvastatin alone).</p><p># See sections 4.4 and 4.5 for clinical significance.</p><p>* Contains one or more components that inhibit CYP3A4 and can increase plasma concentrations of medicinal products metabolised by CYP3A4. Intake of one 240 ml glass of grapefruit juice also resulted in a decreased AUC of 20.4% for the active orthohydroxy metabolite. Large quantities of grapefruit juice (over 1.2 l daily for 5 days) increased AUC of atorvastatin 2.5 fold and AUC of active (atorvastatin and metabolites) HMG-CoA reductase inhibitors 1.3 fold.</p><p>** Ratio based on a single sample taken 8-16 h post dose.</p><p>OD = once daily; SD = single dose; BID = twice daily; TID = three times daily; QID = four times daily</p><p>&nbsp;</p><p>Table 2: Effect of atorvastatin on the pharmacokinetics of co-administered medicinal products</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Atorvastatin and dosing regimen</p></td><td colspan="3" style="vertical-align:top"><p>Co-administered medicinal product</p></td></tr><tr><td style="vertical-align:top"><p>Medicinal product/Dose (mg)</p></td><td style="vertical-align:top"><p>Ratio of AUC&amp;</p></td><td style="vertical-align:top"><p>Clinical Recommendation</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>80 mg OD for 10 days</p></td><td style="vertical-align:top"><p>Digoxin 0.25 mg OD, 20 days</p></td><td style="vertical-align:top"><p>1.15</p></td><td style="vertical-align:top"><p>Patients taking digoxin should be monitored appropriately.</p></td></tr><tr><td style="vertical-align:top"><p>40 mg OD for 22 days</p></td><td style="vertical-align:top"><p>Oral contraceptive OD, 2 months</p><p>-&nbsp; norethindrone 1 mg</p><p>-&nbsp; ethinyl estradiol 35 &micro;g</p></td><td style="vertical-align:top"><p>1.28</p><p>1.19</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr><tr><td style="vertical-align:top"><p>80 mg OD for 15 days</p></td><td style="vertical-align:top"><p>* Phenazone, 600 mg SD</p></td><td style="vertical-align:top"><p>1.03</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr><tr><td style="vertical-align:top"><p>10 mg, SD</p></td><td style="vertical-align:top"><p>Tipranavir 500 mg</p><p>BID/ritonavir 200 mg BID, 7 days</p></td><td style="vertical-align:top"><p>1.08</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr><tr><td style="vertical-align:top"><p>10 mg, OD for 4 days</p></td><td style="vertical-align:top"><p>Fosamprenavir 1400 mg BID, 14 days</p></td><td style="vertical-align:top"><p>0.73</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr><tr><td style="vertical-align:top"><p>10 mg OD for 4 days</p></td><td style="vertical-align:top"><p>Fosamprenavir 700 mg</p><p>BID/ritonavir 100 mg BID, 14 days</p></td><td style="vertical-align:top"><p>0.99</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr></tbody></table><p>&nbsp;</p><p>&amp; Represents ratio of treatments (co-administered medicinal product plus atorvastatin versus atorvastatin alone).</p><p>* Co-administration of multiple doses of atorvastatin and phenazone showed little or no detectable effect in the clearance of phenazone.</p><p>OD = once daily; SD = single dose; BID = twice daily</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>&nbsp;</p><p>Women of child-bearing potential should use appropriate contraceptive measures during treatment (see section 4.3).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>Tulip is contraindicated during pregnancy (see section 4.3). Safety in pregnant women has not been established. No controlled clinical trials with atorvastatin have been conducted in pregnant women. Rare reports of congenital anomalies following intrauterine exposure to HMG- CoA reductase inhibitors have been received. Studies in animals have shown toxicity to reproduction (see section 5.3).</p><p>&nbsp;</p><p>Maternal treatment with atorvastatin may reduce the foetal levels of mevalonate which is a precursor of cholesterol biosynthesis. Atherosclerosis is a chronic process, and ordinarily discontinuation of lipid-lowering medicinal products during pregnancy should have little impact on the long-term risk associated with primary hypercholesterolaemia.</p><p>&nbsp;</p><p>For these reasons, Tulip should not be used in women who are pregnant, trying to become pregnant or suspect they are pregnant. Treatment with Tulip should be suspended for the duration of pregnancy or until it has been determined that the woman is not pregnant (see section 4.3.)</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether atorvastatin or its metabolites are excreted in human milk. In rats, plasma concentrations of atorvastatin and its active metabolites are similar to those in milk (see section 5.3). Because of the potential for serious adverse reactions, women taking Tulip should not breast-feed their infants (see section 4.3). Atorvastatin is contraindicated during breast- feeding (see section 4.3).</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>In animal studies atorvastatin had no effect on male or female fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tulip has negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the atorvastatin placebo-controlled clinical trial database of 16,066 (8755 atorvastatin vs. 7311 placebo) patients treated for a mean period of 53 weeks, 5.2% of patients on atorvastatin discontinued due to adverse reactions compared to 4.0% of the patients on placebo.</p><p>&nbsp;</p><p>Based on data from clinical studies and extensive post-marketing experience, the following table presents the adverse reaction profile for atorvastatin.</p><p>&nbsp;</p><p>&nbsp;</p><p>Estimated frequencies of reactions are ranked according to the following convention: common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><u>Infections and infestations </u>Common: nasopharyngitis.</p><p>&nbsp;</p><p><u>Blood and lymphatic system disorders </u>Rare: thrombocytopenia.</p><p>&nbsp;</p><p><u>Immune system disorders </u>Common: allergic reactions. Very rare: anaphylaxis.</p><p>&nbsp;</p><p><u>Metabolism and nutrition disorders </u>Common: hyperglycaemia.</p><p>Uncommon: hypoglycaemia, weight gain, anorexia</p><p>&nbsp;</p><p><u>Psychiatric disorders</u></p><p>Uncommon: nightmare, insomnia.</p><p>&nbsp;</p><p><u>Nervous system disorders </u>Common: headache.</p><p>Uncommon: dizziness, paraesthesia, hypoesthesia, dysgeusia, amnesia. Rare: peripheral neuropathy.</p><p>&nbsp;</p><p><u>Eye disorders</u></p><p>Uncommon: vision blurred. Rare: visual disturbance.</p><p>&nbsp;</p><p><u>Ear and labyrinth disorders </u>Uncommon: tinnitus</p><p>Very rare: hearing loss.</p><p>&nbsp;</p><p><u>Respiratory, thoracic and mediastinal disorders </u>Common: pharyngolaryngeal pain, epistaxis.</p><p>&nbsp;</p><p><u>Gastrointestinal disorders</u></p><p>Common: constipation, flatulence, dyspepsia, nausea, diarrhoea.</p><p>Uncommon: vomiting, abdominal pain upper and lower, eructation, pancreatitis.</p><p>&nbsp;</p><p><u>Hepatobiliary disorders </u>Uncommon: hepatitis. Rare: cholestasis.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp; Very rare: hepatic failure.</p><p>&nbsp;</p><p><u>Skin and subcutaneous tissue disorders </u>Uncommon: urticaria, skin rash, pruritus, alopecia.</p><p>Rare: angioneurotic oedema, dermatitis bullous including erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis.</p><p>&nbsp;</p><p><u>Musculoskeletal and connective tissue disorders</u></p><p>Common: myalgia, arthralgia, pain in extremity, muscle spasms, joint swelling, back pain. Uncommon: neck pain, muscle fatigue.</p><p>Rare: myopathy, myositis, rhabdomyolysis, muscle rupture, tendonopathy, sometimes complicated by rupture.</p><p>Very rare: lupus-like syndrome</p><p>Not known: immune mediated necrotising myopathy (see section 4.4).</p><p>&nbsp;</p><p><u>Reproductive system and breast disorders </u>Very rare: gynaecomastia.</p><p>&nbsp;</p><p><u>General disorders and administration site conditions</u></p><p>Uncommon: malaise, asthenia, chest pain, peripheral oedema, fatigue, pyrexia.</p><p>&nbsp;</p><p><u>Investigations</u></p><p>Common: liver function test abnormal, blood creatine kinase increased. Uncommon: white blood cells urine positive.</p><p>&nbsp;</p><p>As with other HMG-CoA reductase inhibitors elevated serum transaminases have been reported in patients receiving atorvastatin. These changes were usually mild, transient, and did not require interruption of treatment. Clinically important (&gt; 3 times upper normal limit) elevations in serum transaminases occurred in 0.8% patients on atorvastatin. These elevations were dose related and were reversible in all patients.</p><p>&nbsp;</p><p>Elevated serum creatine kinase (CK) levels greater than 3 times upper limit of normal occurred in 2.5% of patients on atorvastatin, similar to other HMG-CoA reductase inhibitors in clinical trials. Levels above 10 times the normal upper range occurred in 0.4% atorvastatin-treated patients (see section 4.4).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Paediatric patients aged from 10 to 17 years of age treated with atorvastatin had an adverse experience profile generally similar to that of patients treated with placebo, the most common adverse experiences observed in both groups, regardless of causality assessment, were infections. No clinically significant effect on growth and sexual maturation was observed in a 3-year study based on the assessment of overall maturation and development, assessment of Tanner Stage, and measurement</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp; of height and weight. The safety and tolerability profile in paediatric patients was similar to the &nbsp;&nbsp;known safety profile of atorvastatin in adult patients.</p><p>&nbsp;</p><p>The clinical safety database includes safety data for 520 paediatric patients who received atorvastatin, among which 7 patients were &lt; 6 years old, 121 patients were in the age range of 6 to 9, and 392 patients were in the age range of 10 to 17.</p><p>&nbsp;</p><p>Based on the data available, the frequency, type and severity of adverse reactions in children is similar to adults.</p><p>&nbsp;</p><p>The following adverse events have been reported with some statins:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sexual dysfunction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exceptional cases of interstitial lung disease, especially with long term therapy (see section 4.4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes Mellitus: Frequency will depend on the presence or absence of risk factors (fasting blood glucose &ge; 5.6 mmol/L, BMI&gt;30kg/m2, raised triglycerides, history of hypertension).</p><p>&nbsp;</p><p>To reports any side effect(s):</p><p>&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>-&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext 2317-2356-2340</p><p>-&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Specific treatment is not available for Tulip overdose. Should an overdose occur, the patient should be treated symptomatically and supportive measures instituted, as required. Liver function tests should be performed and serum CK levels should be monitored. Due to extensive atorvastatin binding to plasma proteins, haemodialysis is not expected to significantly enhance atorvastatin clearance.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Lipid modifying agents, HMG-CoA-reductase inhibitors, ATC code: C10AA05</p><p>&nbsp;</p><p>Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme responsible for the conversion of 3-hydroxy-3-methyl-glutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. Triglycerides and cholesterol in the liver are incorporated into very low-density lipoproteins (VLDL) and released into the plasma for delivery to peripheral tissues. Low-density lipoprotein (LDL) is formed from VLDL and is catabolised primarily through</p><p>&nbsp;</p><p>&nbsp;</p><p>the receptor with high affinity to LDL (LDL receptor).</p><p>&nbsp;</p><p>Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.</p><p>&nbsp;</p><p>Atorvastatin reduces LDL production and the number of LDL particles. Atorvastatin produces a profound and sustained increase in LDL receptor activity coupled with a beneficial change in the quality of circulating LDL particles. Atorvastatin is effective in reducing LDL-C in patients with homozygous familial hypercholesterolaemia, a population that has not usually responded to lipid- lowering medicinal products.</p><p>&nbsp;</p><p>Atorvastatin has been shown to reduce concentrations of total-C (30% - 46%), LDL-C (41% - 61%), apolipoprotein B (34% - 50%), and triglycerides (14% - 33%) while producing variable increases in HDL-C and apolipoprotein A1 in a dose response study. These results are consistent in patients with heterozygous familial hypercholesterolaemia, nonfamilial forms of hypercholesterolaemia, and mixed hyperlipidaemia, including patients with noninsulin-dependent diabetes mellitus.</p><p>&nbsp;</p><p>Reductions in total-C, LDL-C, and apolipoprotein B have been proven to reduce risk for cardiovascular events and cardiovascular mortality.</p><p>&nbsp;</p><p><u>Homozygous familial hypercholesterolaemia</u></p><p>&nbsp;</p><p>In a multicenter 8 week open-label compassionate-use study with an optional extension phase of variable length, 335 patients were enrolled, 89 of which were identified as homozygous familial hypercholesterolaemia patients. From these 89 patients, the mean percent reduction in LDL-C was approximately 20%. Atorvastatin was administered at doses up to 80 mg/day.</p><p>&nbsp;</p><p><u>Atherosclerosis</u></p><p>&nbsp;</p><p>In the Reversing Atherosclerosis with Aggressive Lipid- Lowering Study (REVERSAL), the effect of intensive lipid lowering with atorvastatin 80 mg and standard degree of lipid lowering with pravastatin 40 mg on coronary atherosclerosis was assessed by intravascular ultrasound (IVUS), during angiography, in patients with coronary heart disease. In this randomised, double- blind, multicenter, controlled clinical trial, IVUS was performed at baseline and at 18 months in 502 patients. In the atorvastatin group (n=253), there was no progression of atherosclerosis.</p><p>&nbsp;</p><p>The median percent change, from baseline, in total atheroma volume (the primary study criteria) was - 0.4% (p=0.98) in the atorvastatin group and +2.7% (p=0.001) in the pravastatin group (n=249). When compared to pravastatin the effects of atorvastatin were statistically significant (p=0.02). The effect of intensive lipid lowering on cardiovascular endpoints (e. g. need for revascularisation, non-fatal myocardial infarction, coronary death) was not investigated in this study.</p><p>&nbsp;</p><p>In the atorvastatin group, LDL-C was reduced to a mean of 2.04 mmol/L &plusmn; 0.8 (78.9 mg/dl &plusmn; 30) from</p><p>&nbsp;</p><p>&nbsp;</p><p>baseline 3.89 mmol/l &plusmn; 0.7 (150 mg/dl &plusmn; 28) and in the pravastatin group, LDL-C was reduced to a mean of 2.85 mmol/l &plusmn; 0.7 (110 mg/dl &plusmn; 26) from baseline 3.89 mmol/l &plusmn; 0.7 (150 mg/dl &plusmn; 26) (p&lt;0.0001). Atorvastatin also significantly reduced mean TC by 34.1% (pravastatin: -18.4%, p&lt;0.0001), mean TG levels by 20% (pravastatin: -6.8%, p&lt;0.0009), and mean apolipoprotein B by 39.1% (pravastatin: -22.0%, p&lt;0.0001). Atorvastatin increased mean HDL-C by 2.9% (pravastatin:</p><p>+5.6%, p=NS). There was a 36.4% mean reduction in CRP in the atorvastatin group compared to a 5.2% reduction in the pravastatin group (p&lt;0.0001).</p><p>&nbsp;</p><p>Study results were obtained with the 80 mg dose strength. Therefore, they cannot be extrapolated to the lower dose strengths.</p><p>&nbsp;</p><p>The safety and tolerability profiles of the two treatment groups were comparable.</p><p>&nbsp;</p><p>The effect of intensive lipid lowering on major cardiovascular endpoints was not investigated in this study. Therefore, the clinical significance of these imaging results with regard to the primary and secondary prevention of cardiovascular events is unknown.</p><p>&nbsp;</p><p><u>Acute coronary syndrome</u></p><p>&nbsp;</p><p>&nbsp;</p><p>In the MIRACL study, atorvastatin 80 mg has been evaluated in 3,086 patients (atorvastatin n=1,538; placebo n=1,548) with an acute coronary syndrome (non Q-wave MI or unstable angina). Treatment was initiated during the acute phase after hospital admission and lasted for a period of 16 weeks.</p><p>Treatment with atorvastatin 80 mg/day increased the time to occurrence of the combined primary endpoint, defined as death from any cause, nonfatal MI, resuscitated cardiac arrest, or angina pectoris with evidence of myocardial ischaemia requiring hospitalisation, indicating a risk reduction by 16% (p=0.048). This was mainly due to a 26% reduction in re-hospitalisation for angina pectoris with evidence of myocardial ischaemia (p=0.018). The other secondary endpoints did not reach statistical significance on their own (overall: Placebo: 22.2%, Atorvastatin: 22.4%).</p><p>&nbsp;</p><p>The safety profile of atorvastatin in the MIRACL study was consistent with what is described in section 4.8.</p><p>&nbsp;</p><p><u>Prevention of cardiovascular disease</u></p><p>&nbsp;</p><p>The effect of atorvastatin on fatal and non-fatal coronary heart disease was assessed in a randomised, double-blind, placebo-controlled study, the Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm (ASCOT-LLA). Patients were hypertensive, 40-79 years of age, with no previous myocardial infarction or treatment for angina, and with TC levels &le;6.5 mmol/l (251 mg/dl). All patients had at least 3 of the pre-defined cardiovascular risk factors: male gender, age &ge;55 years, smoking, diabetes, history of CHD in a first-degree relative, TC:HDL-C &gt;6, peripheral vascular disease, left ventricular hypertrophy, prior cerebrovascular event, specific ECG abnormality, proteinuria/albuminuria. Not all included patients were estimated to have a high risk for a first cardiovascular event.</p><p>&nbsp;</p><p>&nbsp;</p><p>Patients were treated with anti-hypertensive therapy (either amlodipine or atenolol-based regimen) and either atorvastatin 10 mg daily (n=5,168) or placebo (n=5,137).</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_84" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='width:464.7pt;height:132.25pt;visibility:visible;
 mso-wrap-style:square;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
     style='margin-left:-.25pt;border-collapse:collapse;mso-table-layout-alt:
     fixed;mso-padding-alt:0in 0in 0in 0in'>
     <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:53.05pt;
      mso-height-rule:exactly'>
      <td width=215 valign=top style='width:161.15pt;border:solid black 1.0pt;
      mso-border-alt:solid black .5pt;padding:0in 0in 0in 0in;height:53.05pt;
      mso-height-rule:exactly'>
      <p class=TableParagraph style='margin-left:0in;punctuation-wrap:simple;
      mso-line-break-override:restrictions'><span style='font-size:11.0pt'>Event</span><o:p></o:p></p>
      </td>
      <td width=89 valign=top style='width:67.1pt;border:solid black 1.0pt;
      border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:
      solid black .5pt;padding:0in 0in 0in 0in;height:53.05pt;mso-height-rule:
      exactly'>
      <p class=TableParagraph align=center style='margin-top:0in;margin-right:
      10.45pt;margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;
      text-align:center;line-height:101%;punctuation-wrap:simple;mso-line-break-override:
      restrictions'><span style='font-size:11.0pt;line-height:101%'>Relative
      Risk Reduction (%)</span><o:p></o:p></p>
      </td>
      <td width=99 valign=top style='width:74.5pt;border:solid black 1.0pt;
      border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:
      solid black .5pt;padding:0in 0in 0in 0in;height:53.05pt;mso-height-rule:
      exactly'>
      <p class=TableParagraph style='margin-top:0in;margin-right:6.45pt;
      margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:justify;
      line-height:101%;punctuation-wrap:simple;mso-line-break-override:restrictions'><span
      style='font-size:11.0pt;line-height:101%'>No. of Events (Atorvastatin vs
      Placebo)</span><o:p></o:p></p>
      </td>
      <td width=94 valign=top style='width:70.8pt;border:solid black 1.0pt;
      border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:
      solid black .5pt;padding:0in 0in 0in 0in;height:53.05pt;mso-height-rule:
      exactly'>
      <p class=TableParagraph align=center style='margin-top:0in;margin-right:
      10.55pt;margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;
      text-align:center;line-height:98%;punctuation-wrap:simple;mso-line-break-override:
      restrictions'><span style='font-size:11.0pt;line-height:98%'>Absolute
      Risk Reduction</span><span style='font-size:7.0pt;line-height:98%;
      position:relative;top:-5.0pt;mso-text-raise:5.0pt'>1 </span><span
      style='font-size:11.0pt;line-height:98%'>(%)</span><o:p></o:p></p>
      </td>
      <td width=120 valign=top style='width:90.25pt;border:solid black 1.0pt;
      border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:
      solid black .5pt;padding:0in 0in 0in 0in;height:53.05pt;mso-height-rule:
      exactly'>
      <p class=TableParagraph style='margin-left:0in;punctuation-wrap:simple;
      mso-line-break-override:restrictions'><span style='font-size:11.0pt'>p-value</span><o:p></o:p></p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:1;height:24.0pt;mso-height-rule:exactly'>
      <td width=215 valign=top style='width:161.15pt;border:solid black 1.0pt;
      border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:0in 0in 0in 0in;height:24.0pt;mso-height-rule:exactly'>
      <p class=TableParagraph style='margin-left:0in;punctuation-wrap:simple;
      mso-line-break-override:restrictions'><span style='font-size:11.0pt'>Fatal
      CHD plus non-fatal MI</span><o:p></o:p></p>
      </td>
      <td width=89 valign=top style='width:67.1pt;border-top:none;border-left:
      none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:0in 0in 0in 0in;height:24.0pt;
      mso-height-rule:exactly'>
      <p class=TableParagraph align=center style='margin-top:0in;margin-right:
      10.4pt;margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;
      text-align:center;punctuation-wrap:simple;mso-line-break-override:restrictions'><span
      style='font-size:11.0pt'>36%</span><o:p></o:p></p>
      </td>
      <td width=99 valign=top style='width:74.5pt;border-top:none;border-left:
      none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:0in 0in 0in 0in;height:24.0pt;
      mso-height-rule:exactly'>
      <p class=TableParagraph style='margin-left:0in;punctuation-wrap:simple;
      mso-line-break-override:restrictions'><span style='font-size:11.0pt'>100
      vs. 154</span><o:p></o:p></p>
      </td>
      <td width=94 valign=top style='width:70.8pt;border-top:none;border-left:
      none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:0in 0in 0in 0in;height:24.0pt;
      mso-height-rule:exactly'>
      <p class=TableParagraph align=center style='margin-top:0in;margin-right:
      22.6pt;margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;
      text-align:center;punctuation-wrap:simple;mso-line-break-override:restrictions'><span
      style='font-size:11.0pt'>1.1%</span><o:p></o:p></p>
      </td>
      <td width=120 valign=top style='width:90.25pt;border-top:none;border-left:
      none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:0in 0in 0in 0in;height:24.0pt;
      mso-height-rule:exactly'>
      <p class=TableParagraph style='margin-left:0in;punctuation-wrap:simple;
      mso-line-break-override:restrictions'><span style='font-size:11.0pt'>0.0005</span><o:p></o:p></p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:2;height:28.3pt;mso-height-rule:exactly'>
      <td width=215 valign=top style='width:161.15pt;border:solid black 1.0pt;
      border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:0in 0in 0in 0in;height:28.3pt;mso-height-rule:exactly'>
      <p class=TableParagraph style='margin-left:0in;line-height:101%;
      punctuation-wrap:simple;mso-line-break-override:restrictions'><span
      style='font-size:11.0pt;line-height:101%'>Total cardiovascular events and
      revascularization procedures</span><o:p></o:p></p>
      </td>
      <td width=89 valign=top style='width:67.1pt;border-top:none;border-left:
      none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:0in 0in 0in 0in;height:28.3pt;
      mso-height-rule:exactly'>
      <p class=TableParagraph align=center style='margin-top:0in;margin-right:
      10.45pt;margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;
      text-align:center;punctuation-wrap:simple;mso-line-break-override:restrictions'><span
      style='font-size:11.0pt'>20%</span><o:p></o:p></p>
      </td>
      <td width=99 valign=top style='width:74.5pt;border-top:none;border-left:
      none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:0in 0in 0in 0in;height:28.3pt;
      mso-height-rule:exactly'>
      <p class=TableParagraph style='margin-left:0in;punctuation-wrap:simple;
      mso-line-break-override:restrictions'><span style='font-size:11.0pt'>389
      vs. 483</span><o:p></o:p></p>
      </td>
      <td width=94 valign=top style='width:70.8pt;border-top:none;border-left:
      none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:0in 0in 0in 0in;height:28.3pt;
      mso-height-rule:exactly'>
      <p class=TableParagraph align=center style='margin-top:0in;margin-right:
      22.6pt;margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;
      text-align:center;punctuation-wrap:simple;mso-line-break-override:restrictions'><span
      style='font-size:11.0pt'>1.9%</span><o:p></o:p></p>
      </td>
      <td width=120 valign=top style='width:90.25pt;border-top:none;border-left:
      none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:0in 0in 0in 0in;height:28.3pt;
      mso-height-rule:exactly'>
      <p class=TableParagraph style='margin-left:0in;punctuation-wrap:simple;
      mso-line-break-override:restrictions'><span style='font-size:11.0pt'>0.0008</span><o:p></o:p></p>
      </td>
     </tr>
     <tr style='mso-yfti-irow:3;mso-yfti-lastrow:yes;height:26.3pt;mso-height-rule:
      exactly'>
      <td width=215 valign=top style='width:161.15pt;border:solid black 1.0pt;
      border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
      padding:0in 0in 0in 0in;height:26.3pt;mso-height-rule:exactly'>
      <p class=TableParagraph style='margin-left:0in;punctuation-wrap:simple;
      mso-line-break-override:restrictions'><span style='font-size:11.0pt'>Total
      coronary events</span><o:p></o:p></p>
      </td>
      <td width=89 valign=top style='width:67.1pt;border-top:none;border-left:
      none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:0in 0in 0in 0in;height:26.3pt;
      mso-height-rule:exactly'>
      <p class=TableParagraph align=center style='margin-top:0in;margin-right:
      10.45pt;margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;
      text-align:center;punctuation-wrap:simple;mso-line-break-override:restrictions'><span
      style='font-size:11.0pt'>29%</span><o:p></o:p></p>
      </td>
      <td width=99 valign=top style='width:74.5pt;border-top:none;border-left:
      none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:0in 0in 0in 0in;height:26.3pt;
      mso-height-rule:exactly'>
      <p class=TableParagraph style='margin-left:0in;punctuation-wrap:simple;
      mso-line-break-override:restrictions'><span style='font-size:11.0pt'>178
      vs 247</span><o:p></o:p></p>
      </td>
      <td width=94 valign=top style='width:70.8pt;border-top:none;border-left:
      none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:0in 0in 0in 0in;height:26.3pt;
      mso-height-rule:exactly'>
      <p class=TableParagraph align=center style='margin-top:0in;margin-right:
      22.6pt;margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;
      text-align:center;punctuation-wrap:simple;mso-line-break-override:restrictions'><span
      style='font-size:11.0pt'>1.4%</span><o:p></o:p></p>
      </td>
      <td width=120 valign=top style='width:90.25pt;border-top:none;border-left:
      none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
      mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
      mso-border-alt:solid black .5pt;padding:0in 0in 0in 0in;height:26.3pt;
      mso-height-rule:exactly'>
      <p class=TableParagraph style='margin-left:0in;punctuation-wrap:simple;
      mso-line-break-override:restrictions'><span style='font-size:11.0pt'>0.0006</span><o:p></o:p></p>
      </td>
     </tr>
    </table>
    <p class=MsoBodyText style='punctuation-wrap:simple;mso-line-break-override:
    restrictions'><span style='font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="624" height="181" alt="Text Box: Event	Relative Risk Reduction (%)	No. of Events (Atorvastatin vs Placebo)	Absolute Risk Reduction1 (%)	p-value
Fatal CHD plus non-fatal MI	36%	100 vs. 154	1.1%	0.0005
Total cardiovascular events and revascularization procedures	20%	389 vs. 483	1.9%	0.0008
Total coronary events	29%	178 vs 247	1.4%	0.0006

" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:464.7pt;height:132.25pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>The absolute and relative risk reduction effect of atorvastatin was as follows:</p><p>&nbsp;</p><p>1Based on difference in crude events rates occurring over a median follow-up of 3.3 years. CHD = coronary heart disease; MI = myocardial infarction.</p><p>&nbsp;</p><p>Total mortality and cardiovascular mortality were not significantly reduced (185 vs. 212 events, p=0.17 and 74 vs. 82 events, p=0.51). In the subgroup analyses by gender (81% males, 19% females), a beneficial effect of atorvastatin was seen in males but could not be established in females possibly due to the low event rate in the female subgroup. Overall and cardiovascular mortality were numerically higher in the female patients (38 vs. 30 and 17 vs. 12), but this was not statistically significant. There was significant treatment interaction by antihypertensive baseline therapy. The primary endpoint (fatal CHD plus non-fatal MI) was significantly reduced by atorvastatin in patients treated with amlodipine (HR 0.47 (0.32-0.69), p=0.00008), but not in those treated with atenolol (HR 0.83 (0.59-1.17), p=0.287).</p><p>&nbsp;</p><p>The effect of atorvastatin on fatal and non-fatal cardiovascular disease was also assessed in a randomised, double-blind, multicenter, placebo-controlled trial, the Collaborative Atorvastatin Diabetes Study (CARDS) in patients with type 2 diabetes, 40-75 years of age, without prior history of cardiovascular disease, and with LDL-C &le;4.14 mmol/l (160 mg/dl) and TG &le;6.78 mmol/l (600 mg/dl). All patients had at least 1 of the following risk factors: hypertension, current smoking, retinopathy, microalbuminuria or macroalbuminuria.</p><p>&nbsp;</p><p>Patients were treated with either atorvastatin 10 mg daily (n=1,428) or placebo (n=1,410) for a median follow-up of 3.9 years.</p><p>&nbsp;</p><p>The absolute and relative risk reduction effect of atorvastatin was as follows:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Event</p></td><td style="vertical-align:top"><p>Relative Risk Reduction (%)</p></td><td style="vertical-align:top"><p>No. of Events (Atorvastatin vs Placebo)</p></td><td style="vertical-align:top"><p>Absolute Risk Reduction1 (%)</p></td><td style="vertical-align:top"><p>p-value</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>1Based on difference in crude events rates occurring over a median follow-up of 3.9 years.</p><p>AMI = acute myocardial infarction; CABG = coronary artery bypass graft; CHD = coronary heart disease; MI = myocardial infarction; PTCA = percutaneous transluminal coronary angioplasty.</p><p>&nbsp;</p><p>There was no evidence of a difference in the treatment effect by patient&rsquo;s gender, age, or baseline LDL-C level. A favourable trend was observed regarding the mortality rate (82 deaths in the placebo group vs. 61 deaths in the atorvastatin group, p=0.0592).</p><p>&nbsp;</p><p><u>Recurrent stroke</u></p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Major cardiovascular events (fatal and non-fatal AMI, silent MI, acute CHD death, unstable angina, CABG, PTCA, revascularization, stroke)</p></td><td style="vertical-align:top"><p>37%</p></td><td style="vertical-align:top"><p>83 vs. 127</p></td><td style="vertical-align:top"><p>3.2%</p></td><td style="vertical-align:top"><p>0.0010</p></td></tr><tr><td style="vertical-align:top"><p>MI (fatal and non-fatal AMI, silent MI)</p></td><td style="vertical-align:top"><p>42%</p></td><td style="vertical-align:top"><p>38 vs 64</p></td><td style="vertical-align:top"><p>1.9%</p></td><td style="vertical-align:top"><p>0.0070</p></td></tr><tr><td style="vertical-align:top"><p>Strokes (Fatal and non-fatal)</p></td><td style="vertical-align:top"><p>48%</p></td><td style="vertical-align:top"><p>21 vs. 39</p></td><td style="vertical-align:top"><p>1.3%</p></td><td style="vertical-align:top"><p>0.0163</p></td></tr></tbody></table><p>&nbsp;</p><p>In the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study, the effect of atorvastatin 80 mg daily or placebo on stroke was evaluated in 4731 patients who had a stroke or transient ischaemic attack (TIA) within the preceding 6 months and no history of coronary heart disease (CHD). Patients were 60% male, 21-92 years of age (average age 63 years), and had an average baseline LDL of 133 mg/dL (3.4 mmol/L). The mean LDL-C was 73 mg/dL (1.9 mmol/L) during treatment with atorvastatin and 129 mg/dL (3.3 mmol/L) during treatment with placebo.</p><p>Median follow-up was 4.9 years.</p><p>&nbsp;</p><p>Atorvastatin 80 mg reduced the risk of the primary endpoint of fatal or non-fatal stroke by 15% (HR 0.85; 95% CI, 0.72-1.00; p=0.05 or 0.84; 95% CI, 0.71-0.99; p=0.03 after adjustment for baseline factors) compared to placebo. All cause mortality was 9.1% (216/2365) for atorvastatin versus 8.9% (211/2366) for placebo.</p><p>&nbsp;</p><p>In a post-hoc analysis, atorvastatin 80 mg reduced the incidence of ischaemic stroke (218/2365, 9.2% vs. 274/2366, 11.6%, p=0.01) and increased the incidence of haemorrhagic stroke (55/2365, 2.3% vs. 33/2366, 1.4%, p=0.02) compared to placebo.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The risk of haemorrhagic stroke was increased in patients who entered the study with prior haemorrhagic stroke (7/45 for atorvastatin versus 2/48 for placebo; HR 4.06; 95% CI, 0.84- 19.57), and the risk of ischaemic stroke was similar between groups (3/45 for atorvastatin versus 2/48 for placebo; HR 1.64; 95% CI, 0.27-9.82).</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The risk of haemorrhagic stroke was increased in patients who entered the study with prior lacunar infarct (20/708 for atorvastatin versus 4/701 for placebo; HR 4.99; 95% CI, 1.71-</p><p>&nbsp;</p><p>&nbsp;</p><p>14.61), but the risk of ischaemic stroke was also decreased in these patients (79/708 for atorvastatin versus 102/701 for placebo; HR 0.76; 95% CI, 0.57-1.02). It is possible that the net risk of stroke is increased in patients with prior lacunar infarct who receive atorvastatin 80 mg/day.</p><p>&nbsp;</p><p>All cause mortality was 15.6% (7/45) for atorvastatin versus 10.4% (5/48) in the subgroup of patients with prior haemorrhagic stroke. All cause mortality was 10.9% (77/708) for atorvastatin versus 9.1% (64/701) for placebo in the subgroup of patients with prior lacunar infarct.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p><em><u>Heterozygous familial hypercholesterolaemia in paediatric patients aged 6 &ndash; 17 years old</u></em></p><p><em>&nbsp;</em></p><p>An 8-week, open-label study to evaluate pharmacokinetics, pharmacodynamics, and safety and tolerability of atorvastatin was conducted in children and adolescents with genetically confirmed heterozygous familial hypercholesterolaemia and baseline LDL-C &ge;4 mmol/L. A total of 39 children and adolescents, 6 to 17 years of age, were enrolled. Cohort A included 15 children, 6 to 12 years of age and at Tanner Stage 1. Cohort B included 24 children, 10 to 17 years of age and at Tanner</p><p>Stage &ge;2.</p><p>&nbsp;</p><p>The initial dose of atorvastatin was 5 mg daily of a chewable tablet in Cohort A and 10 mg daily of a tablet formulation in Cohort B. The atorvastatin dose was permitted to be doubled if a subject had not attained target LDL-C of &lt;3.35 mmol/L at Week 4 and if atorvastatin was well tolerated.</p><p>&nbsp;</p><p>Mean values for LDL-C, TC, VLDL-C, and Apo B decreased by week 2 among all subjects. For subjects whose dose was doubled, additional decreases were observed as early as 2 weeks, at the first assessment, after dose escalation. The mean percent decreases in lipid parameters were similar for both cohorts, regardless of whether subjects remained at their initial dose or doubled their initial dose. At Week 8, on average, the percent change from baseline in LDL-C and TC was approximately 40% and 30%, respectively, over the range of exposures.</p><p>&nbsp;</p><p>In a second open label, single arm study, 271 male and female HeFH children 6-15 years of age were enrolled and treated with atorvastatin for up to three years. Inclusion in the study required confirmed HeFH and a baseline LDL-C level &ge; 4 mmol/L (approximately 152 mg/dL). The study included 139 children at Tanner 1 developmental stage (generally ranging from 6-10 years of age). The dosage of atorvastatin (once daily) was initiated at 5 mg (chewable tablet) in children less than 10 years of age. Children age 10 and above were initiated at 10 mg atorvastatin (once daily). All children could titrate to higher doses to achieve a target of &lt; 3.35 mmol/l LDL-C. The mean weighted dose for children aged 6 to 9 years was 19.6 mg and the mean weighted dose for children aged 10 years and above was</p><p>23.9 mg.</p><p>The mean (+/- SD) baseline LDL-C value was 6.12 (1.26) mmol/L which was approximately 233 (48) mg/dL. See table 3 below for final results.</p><p>The data were consistent with no medicinal product effect on any of the parameters of growth and development (i.e., height, weight, BMI, Tanner stage, Investigator assessment of Overall Maturation</p><p>&nbsp;</p><p>&nbsp;</p><p>and Development) in paediatric and adolescent subjects with HeFH receiving atorvastatin treatment over the 3 year study. There was no Investigator-assessed medicinal product effect noted in height, weight, BMI by age or by gender by visit.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>TABLE 3 <u>Lipid-lowering Effects of Atorvastatin in Adolescent Boys and Girls with Heterozygous Familial</u></strong></p><p><strong>Hypercholesterolemia (mmol/L)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Timepoint</p></td><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>TC (S.D.)</p></td><td style="vertical-align:top"><p>LDL-C (S.D.)</p></td><td style="vertical-align:top"><p>HDL-C (S.D.)</p></td><td style="vertical-align:top"><p>TG (S.D.)</p></td><td style="vertical-align:top"><p>Apo B (S.D.)#</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>271</p></td><td style="vertical-align:top"><p>7.86</p><p>(1.30)</p></td><td style="vertical-align:top"><p>6.12</p><p>(1.26)</p></td><td style="vertical-align:top"><p>1.314</p><p>(0.2663)</p></td><td style="vertical-align:top"><p>0.93</p><p>(0.47)</p></td><td style="vertical-align:top"><p>1.42 (0.28)**</p></td></tr><tr><td style="vertical-align:top"><p>Month 30</p></td><td style="vertical-align:top"><p>206</p></td><td style="vertical-align:top"><p>4.95 (0.77)*</p></td><td style="vertical-align:top"><p>3.25</p><p>(0.67)</p></td><td style="vertical-align:top"><p>1.327</p><p>(0.2796)</p></td><td style="vertical-align:top"><p>0.79 (0.38)*</p></td><td style="vertical-align:top"><p>0.90 (0.17)*</p></td></tr><tr><td style="vertical-align:top"><p>Month 36/ET</p></td><td style="vertical-align:top"><p>240</p></td><td style="vertical-align:top"><p>5.12</p><p>(0.86)</p></td><td style="vertical-align:top"><p>3.45</p><p>(0.81)</p></td><td style="vertical-align:top"><p>1.308</p><p>(0.2739)</p></td><td style="vertical-align:top"><p>0.78</p><p>(0.41)</p></td><td style="vertical-align:top"><p>0.93</p><p>(0.20)***</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>TC= total cholesterol; LDL-C = low density cholesterol-C; HDL-C = high density cholesterol-C; TG</p><p>= triglycerides; Apo B = apolipoprotein B; &ldquo;Month 36/ET&rdquo; included final visit data for subjects who ended participation prior to the scheduled 36 month timepoint as well as full 36 month data for subjects competing the 36 month participation; &ldquo;*&rdquo;= Month 30 N for this parameter was 207; &ldquo;**&rdquo;= Baseline N for this parameter was 270; &ldquo;***&rdquo; = Month 36/ET N for this parameter was 243; &ldquo;#&rdquo;=g/L for Apo B.</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Heterozygous familial hypercholesterolaemia in paediatric patients aged 10 &ndash; 17 years old</u></em></p><p><em>&nbsp;</em></p><p>In a double-blind, placebo controlled study followed by an open-label phase, 187 boys and postmenarchal girls 10-17 years of age (mean age 14.1 years) with heterozygous familial hypercholesterolaemia (FH) or severe hypercholesterolaemia were randomised to atorvastatin (n=140) or placebo (n=47) for 26 weeks and then all received atorvastatin for 26 weeks. The dosage of atorvastatin (once daily) was 10 mg for the first 4 weeks and up-titrated to 20 mg if the LDL-C level was &gt;3.36 mmol/l. Atorvastatin significantly decreased plasma levels of total-C, LDL-C, triglycerides, and apolipoprotein B during the 26 week double-blind phase. The mean achieved LDL- C value was 3.38 mmol/l (range: 1.81-6.26 mmol/l) in the atorvastatin group compared to 5.91 mmol/l (range: 3.93-9.96 mmol/l) in the placebo group during the 26-week double-blind phase.</p><p>&nbsp;</p><p>An additional paediatric study of atorvastatin versus colestipol in patients with hypercholesterolaemia aged 10-18 years demonstrated that atorvastatin (N=25) caused a significant reduction in LDL-C at week 26 (p&lt;0.05) compared with colestipol (N=31).</p><p>&nbsp;</p><p>A compassionate use study in patients with severe hypercholesterolaemia (including homozygous hypercholesterolaemia) included 46 paediatric patients treated with atorvastatin titrated according to response (some subjects received 80 mg atorvastatin per day). The study lasted 3 years: LDL- cholesterol was lowered by 36%.</p><p>&nbsp;</p><p>The long-term efficacy of atorvastatin therapy in childhood to reduce morbidity and mortality in</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp; adulthood has not been established.</p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with atorvastatin in children aged 0 to less than 6 years in the treatment of heterozygous hypercholesterolaemia and in children aged 0 to less than 18 years in the treatment of homozygous familial hypercholesterolaemia, combined (mixed) hypercholesterolaemia, primary hypercholesterolaemia and in the prevention of cardiovascular events (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>Atorvastatin is rapidly absorbed after oral administration; maximum plasma concentrations (Cmax) occur within 1 to 2 hours. Extent of absorption increases in proportion to atorvastatin dose. After oral administration, atorvastatin film-coated tablets are 95% to 99% bioavailable compared to the oral solution. The absolute bioavailability of atorvastatin is approximately 12% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>Mean volume of distribution of atorvastatin is approximately 381 l. Atorvastatin is &ge; 98% bound to plasma proteins.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Atorvastatin is metabolised by cytochrome P450 3A4 to ortho- and parahydroxylated derivatives and various beta-oxidation products. Apart from other pathways these products are further metabolised via glucuronidation. <em>In vitro</em>, inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Atorvastatin is eliminated primarily in bile following hepatic and/or extrahepatic metabolism. However, atorvastatin does not appear to undergo significant enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours. The half-life of inhibitory activity for HMG-CoA reductase is approximately 20 to 30 hours due to the contribution of active metabolites.</p><p>Atorvastatin is a substrate of the hepatic transporters, organic anion-transporting polypeptide 1B1 (OATP1B1) and 1B3 (OATP1B3) transporter. Metabolites of atorvastatin are substrates of OATP1B1. Atorvastatin is also identified as a substrate of the efflux transporters multi-drug</p><p>&nbsp;</p><p>&nbsp;</p><p>resistance protein 1 (MDR1) and breast cancer resistance protein (BCRP), which may limit the intestinal absorption and biliary clearance of atorvastatin.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p>Plasma concentrations of atorvastatin and its active metabolites are higher in healthy elderly subjects than in young adults while the lipid effects were comparable to those seen in younger patient populations.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>In an open-label, 8-week study, Tanner Stage 1 (N=15) and Tanner Stage &ge;2 (N=24) paediatric patients (ages 6-17 years) with heterozygous familial hypercholesterolemia and baseline LDL-C &ge;4 mmol/L were treated with 5 or 10 mg of chewable or 10 or 20 mg of film-coated atorvastatin tablets once daily, respectively. Body weight was the only significant covariate in atorvastatin population PK model. Apparent oral clearance of atorvastatin in paediatric subjects appeared similar to adults when scaled allometrically by body weight. Consistent decreases in LDL-C and TC were observed over the range of atorvastatin and o-hydroxyatorvastatin exposures.</p><p>&nbsp;</p><p><em><u>Gender</u></em></p><p>Concentrations of atorvastatin and its active metabolites in women differ from those in men (Women: approx. 20% higher for Cmax and approx. 10% lower for AUC). These differences were of no clinical significance, resulting in no clinically significant differences in lipid effects among men and women.</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>Renal disease has no influence on the plasma concentrations or lipid effects of atorvastatin and its active metabolites.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>Plasma concentrations of atorvastatin and its active metabolites are markedly increased (approx. 16- fold in Cmax and approx. 11-fold in AUC) in patients with chronic alcoholic liver disease (Child-Pugh B).</p><p>&nbsp;</p><p><em><u>SLOC1B1 polymorphism</u></em></p><p>Hepatic uptake of all HMG-CoA reductase inhibitors including atorvastatin, involves the OATP1B1 transporter. In patients with SLCO1B1 polymorphism there is a risk of increased exposure of atorvastatin, which may lead to an increased risk of rhabdomyolysis (see section 4.4). Polymorphism in the gene encoding OATP1B1 (SLCO1B1 c.521CC) is associated with a 2.4-fold higher atorvastatin exposure (AUC) than in individuals without this genotype variant (c.521TT). A genetically impaired hepatic uptake of atorvastatin is also possible in these patients. Possible consequences for the efficacy are unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Atorvastatin was negative for mutagenic and clastogenic potential in a battery of 4 <em>in vitro </em>tests and 1 <em>in vivo </em>assay. Atorvastatin was not found to be carcinogenic in rats, but high doses in mice (resulting in 6-11 fold the AUC0-24h reached in humans at the highest recommended dose) showed hepatocellular adenomas in males and hepatocellular carcinomas in females.</p><p>&nbsp;</p><p>There is evidence from animal experimental studies that HMG-CoA reductase inhibitors may affect the development of embryos or foetuses. In rats, rabbits and dogs atorvastatin had no effect on fertility and was not teratogenic, however, at maternally toxic doses foetal toxicity was observed in rats and rabbits. The development of the rat offspring was delayed and post-natal survival reduced during exposure of the dams to high doses of atorvastatin. In rats, there is evidence of placental transfer. In rats, plasma concentrations of atorvastatin are similar to those in milk. It is not known whether atorvastatin or its metabolites are excreted in human milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Core:</em></p><p>Sodium lauryl sulfate Microcrystalline cellulose Silica, colloidal anhydrous Maize starch pregelatinised Trometamol</p><p>Iron oxide yellow (E 172) Magnesium stearate</p><p>Talc</p><p>Sodium starch glycolate (type A)</p><p>&nbsp;</p><p><em>Coating: </em>Carmellose sodium Glycerol Trometamol</p><p>Sodium lauryl sulfate Hydroxyethylcellulose</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&ordm;C.</p><p><strong>&nbsp;</strong></p><p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The film-coated tablets are packed in aluminium/aluminium blisters and inserted in a carton.</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_83" o:spid="_x0000_s1029"
 type="#_x0000_t202" style='width:88.35pt;height:13.1pt;visibility:visible;
 mso-wrap-style:square;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="silver" stroked="f">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-top:.05pt;punctuation-wrap:simple;
    mso-line-break-override:restrictions'><i>[AT/H/0305 10 mg]<o:p></o:p></i></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="121" height="21" alt="Text Box: [AT/H/0305 10 mg]" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1028" type="#_x0000_t75" style='width:88.35pt;height:13.1pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>Pack sizes: 7, 14, 28, 30, 56, 60, 63, 90, 91, 100 film-coated tablets</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="Text_x0020_Box_x0020_81" o:spid="_x0000_s1028" type="#_x0000_t202"
 style='width:88.35pt;height:13.1pt;visibility:visible;mso-wrap-style:square;
 mso-left-percent:-10001;mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="silver" stroked="f">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-top:.05pt;punctuation-wrap:simple;
    mso-line-break-override:restrictions'><i>[AT/H/0305 20 mg]<o:p></o:p></i></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="121" height="22" alt="Text Box: [AT/H/0305 20 mg]" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1027" type="#_x0000_t75" style='width:88.35pt;height:13.1pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>Pack sizes: 7, 14, 28, 30, 56, 60, 63, 90, 91, 100 film-coated tablets</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="Text_x0020_Box_x0020_74" o:spid="_x0000_s1027" type="#_x0000_t202"
 style='width:88.35pt;height:13.1pt;visibility:visible;mso-wrap-style:square;
 mso-left-percent:-10001;mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
" fillcolor="silver" stroked="f">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-top:.05pt;punctuation-wrap:simple;
    mso-line-break-override:restrictions'><i>[AT/H/0305 40 mg]<o:p></o:p></i></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="121" height="22" alt="Text Box: [AT/H/0305 40 mg]" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:88.35pt;height:13.1pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>Pack sizes: 7, 14, 28, 30, 56, 60, 63, 90, 91, 100 film-coated tablets</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="Text_x0020_Box_x0020_63" o:spid="_x0000_s1026" type="#_x0000_t202"
 style='width:88.35pt;height:13.1pt;visibility:visible;mso-wrap-style:square;
 mso-left-percent:-10001;mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="silver" stroked="f">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-top:.05pt;punctuation-wrap:simple;
    mso-line-break-override:restrictions'><i>[AT/H/0305 80 mg]<o:p></o:p></i></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="121" height="21" alt="Text Box: [AT/H/0305 80 mg]" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:88.35pt;height:13.1pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>Pack sizes: 7, 28, 30, 50, 60, 90, 98, 100 film-coated tablets</p><p>&nbsp;</p><p><em>[AT/H/0308 10mg, 20mg, 40mg, 80mg]</em></p><p>Pack sizes: 7, 10, 14, 20, 21, 28, 30, 35, 42, 49, 50, 56, 60, 63, 70, 77, 84, 90, 91, 98, 100 film-coated</p><p>tablets</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                       Lek Pharmaceuticals d.d.
       Ljubljana 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                26/11/2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>